

Trastuzumab Clinical Trial

NCT04158258	Hoffmann-La Roche Latin American Cooperative Oncology Group	Breast Cancer	2020/2/21	
NCT02774681	Northwestern University Pfizer National Cancer Institute (NCI)	Breast Carcinoma Metastatic in the Brain Estrogen Receptor Negative HER2+Neu Negative HER2+Neu Positive Progesterone Receptor Negative Recurrent Breast Carcinoma Stage IV Breast Cancer	2016/8/31	Phase 2
NCT03493854	Hoffmann-La Roche	Early Breast Cancer	2018/6/14	Phase 3
NCT03994107	Peking Union Medical College CSPC Ouyi Pharmaceutical Co., Ltd.	Breast Cancer	2019/10/1	Phase 1 Phase 2
NCT04042701	Daiichi Sankyo, Inc. AstraZeneca UK Limited Merck Sharp & Dohme Corp.	Breast Cancer Non-small Cell Lung Carcinoma	2020/2/10	Phase 1
NCT03879577	University of Chicago	Breast Cancer Breast Cancer Female HER2-positive Breast Cancer Breast Cancer Stage II Breast Cancer Stage III	2019/11/25	Phase 2
NCT02569489	HUYA Bioscience International	Breast Cancer	2015/12/1	Phase 1
NCT02091960	Astellas Pharma Global Development, Inc. Medivation LLC, a wholly owned subsidiary of Pfizer Inc. Astellas Pharma Inc	HER2 Amplified Advanced Breast Cancer Human Epidermal Growth Factor Receptor 2 (HER2)	2014/8/28	Phase 2
NCT03368131	Hebei Medical University	Gastroesophageal Junction Adenocarcinoma	2017/12/1	Phase 2
NCT01048099	SCRI Development Innovations, LLC Prometheus Laboratories Genentech, Inc.	Breast Cancer	2011/1/1	Not Applicable
NCT00006015	National Cancer Institute (NCI)	Colorectal Cancer	2000/5/1	Phase 2
NCT00545688	Hoffmann-La Roche	Breast Cancer	2006/6/26	Phase 2
NCT01774851	Merrimack Pharmaceuticals	HER-2 Gene Amplification Esophagus Cancer Gastroesophageal Junction Cancer Stomach Cancer	2013/1/1	Phase 2
NCT01827163	Memorial Sloan Kettering Cancer Center GlaxoSmithKline	HER2-Positive Early Stage Breast Cancer	April 2013	Phase 2
NCT02924883	Hoffmann-La Roche	Metastatic Breast Cancer	2016/9/26	Phase 2
NCT00810017	Medstar Health Research Institute Genentech, Inc.	HER-2 Positive Metastatic Breast Cancer	2009/2/1	Phase 2
NCT00003612	Alliance for Clinical Trials in Oncology National Cancer Institute (NCI)	Breast Cancer	April 1999	Phase 2
NCT00950742	Boehringer Ingelheim	Breast Neoplasms	2009/8/1	Phase 1
NCT04351230	Academic and Community Cancer Research United National Cancer Institute (NCI)	Anatomic Stage IV Breast Cancer AJCC v8 HER2 Positive Breast Carcinoma Metastatic Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8	2020/11/11	Phase 2
NCT03674112	Hoffmann-La Roche	HER2-Positive Early Breast Cancer	2018/12/19	Phase 2
NCT00284180	SCRI Development Innovations,	Breast Neoplasms Breast Cancer	2006/1/1	Phase 2

	LLC Bristol-Myers Squibb			
NCT03529110	Daiichi Sankyo, Inc. Daiichi Sankyo Co., Ltd. AstraZeneca	Breast Cancer	2018/7/20	Phase 3
NCT00003440	National Cancer Institute (NCI)	HER2-negative Breast Cancer HER2-positive Breast Cancer Recurrent Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer	1998/7/1	Phase 3
NCT00009997	NYU Langone Health National Cancer Institute (NCI)	Breast Cancer	1999/3/1	Phase 1
NCT01454804	M.D. Anderson Cancer Center	Advanced Cancers	2011/10/1	Phase 1
NCT00053339	Alliance for Clinical Trials in Oncology National Cancer Institute (NCI)	Stage IV Breast Cancer Recurrent Breast Cancer		Phase 3
NCT04760431	Second Affiliated Hospital, School of Medicine, Zhejiang University Peking University International Hospital Sun Yat-sen University Zhejiang University	HER2-positive Breast Cancer Brain Metastases	2021/10/1	Phase 2
NCT02013765	Hoffmann-La Roche	Urinary Tract Cancer	2001/1/1	Phase 2
NCT02907918	Washington University School of Medicine Pfizer Rising Tide Foundation	Breast Cancer Cancer of Breast Breast Carcinoma	2017/6/30	Phase 2
NCT00968968	Novartis Pharmaceuticals Novartis	Cancer	2010/1/20	Phase 3
NCT01367002	Yale University Genentech, Inc.	Endometrial Cancer	2011/6/1	Phase 2
NCT00041470	University of Washington Amgen Bristol-Myers Squibb GlaxoSmithKline	Breast Cancer	2001/3/1	Phase 1 Phase 2
NCT02656589	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Sun Yat-sen University Huiping Li, M.D., Ph.D., Peking University Cancer Hospital	Breast Cancer	2015/6/1	
NCT00005831	National Cancer Institute (NCI)	Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter Recurrent Bladder Cancer Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter Squamous Cell Carcinoma of the Bladder Stage IV Bladder Cancer Transitional Cell Carcinoma of the Bladder	2000/3/1	Phase 2
NCT02152943	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Advanced Malignant Solid Neoplasm Estrogen Receptor Positive HER2+Neu Positive Postmenopausal Premenopausal Progesterone Receptor Positive Recurrent Breast Carcinoma Refractory Breast Carcinoma Refractory Hormone Receptor Positive Breast Carcinoma Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7	2014/7/17	Phase 1
NCT02436993	University of California, Irvine	Breast Carcinoma	April 2015	Phase 2

NCT04704661	National Cancer Institute (NCI)	<p>Advanced Breast Carcinoma Advanced Colon Carcinoma Advanced Colorectal Carcinoma Advanced Endometrial Carcinoma Advanced Gastric Carcinoma Advanced Gastroesophageal Junction Adenocarcinoma Advanced Malignant Solid Neoplasm Advanced Salivary Gland Carcinoma Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Clinical Stage III Gastric Cancer AJCC v8 Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage IV Gastric Cancer AJCC v8 Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage IVA Gastric Cancer AJCC v8 Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Stage IVB Gastric Cancer AJCC v8 Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 HER2-Positive Breast Carcinoma Malignant Hepatobiliary Neoplasm Metastatic Breast Carcinoma Metastatic Gastroesophageal Junction Adenocarcinoma Metastatic Malignant Solid Neoplasm Pathologic Stage III Gastric Cancer AJCC v8 Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IIIA Gastric Cancer AJCC v8 Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IIIB Gastric Cancer AJCC v8 Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IIIC Gastric Cancer AJCC v8 Pathologic Stage IV Gastric Cancer AJCC v8 Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage IV Breast Cancer AJCC v8 Stage III Colon Cancer AJCC v8 Stage III Colorectal Cancer AJCC v8 Stage III Major Salivary Gland Cancer AJCC</p>	2021/3/5	Phase 1
-------------	---------------------------------	--	----------	---------

		v8 Stage III Uterine Corpus Cancer AJCC v8 Stage IIIA Colon Cancer AJCC v8 Stage IIIA Colorectal Cancer AJCC v8 Stage IIIA Uterine Corpus Cancer AJCC v8 Stage IIIB Colon Cancer AJCC v8 Stage IIIB Colorectal Cancer AJCC v8 Stage IIIB Uterine Corpus Cancer AJCC v8 Stage IIIC Colon Cancer AJCC v8 Stage IIIC Colorectal Cancer AJCC v8 Stage IIIC Uterine Corpus Cancer AJCC v8 Stage IIIC1 Uterine Corpus Cancer AJCC v8 Stage IIIC2 Uterine Corpus Cancer AJCC v8 Stage IV Colon Cancer AJCC v8 Stage IV Colorectal Cancer AJCC v8 Stage IV Major Salivary Gland Cancer AJCC v8 Stage IV Uterine Corpus Cancer AJCC v8 Stage IVA Colon Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVA Major Salivary Gland Cancer AJCC v8 Stage IVA Uterine Corpus Cancer AJCC v8 Stage IVB Colon Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVB Major Salivary Gland Cancer AJCC v8 Stage IVB Uterine Corpus Cancer AJCC v8 Stage IVC Colon Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 Stage IVC Major Salivary Gland Cancer AJCC v8 Unresectable Colorectal Carcinoma Unresectable Gastroesophageal Junction Adenocarcinoma Unresectable Malignant Solid Neoplasm		
NCT03321981	Merus N.V.	Breast Cancer Metastatic	2018/1/15	Phase 2
NCT00003797	Brown University National Cancer Institute (NCI)	Pancreatic Cancer	1999/3/1	Phase 2
NCT00023998	National Cancer Institute (NCI)	Metastatic Osteosarcoma	2001/7/1	Phase 2
NCT00006104	Vanderbilt-Ingram Cancer Center National Cancer Institute (NCI)	Breast Cancer	1998/9/1	Phase 2
NCT03716180	Dana-Farber Cancer Institute Susan G. Komen Breast Cancer Foundation Breast Cancer Research Foundation Terri Brodeur Breast Cancer Foundation	Breast Cancer	2018/11/5	Phase 1
NCT03272477	Palleos Healthcare GmbH Roche Pharma AG WSG WOMEN'S HEALTHCARE STUDY GROUP Cankado Service GmbH	Breast Neoplasms	2017/10/5	Phase 2
NCT01570036	George E. Peoples Genentech, Inc. Sellas Life Sciences Group Cancer Insight, LLC	Breast Cancer	2013/5/21	Phase 2
NCT00613847	Memorial Sloan Kettering Cancer Center	Solid Tumors	2006/10/1	Phase 1

NCT03319459	Fate Therapeutics	HER2 Positive Gastric Cancer Colorectal Cancer Head and Neck Squamous Cell Carcinoma EGFR Positive Solid Tumor Advanced Solid Tumors HER2-positive Breast Cancer Hepatocellular Carcinoma Non Small Cell Lung Cancer Renal Cell Carcinoma Pancreatic Cancer Melanoma	2018/1/18	Phase 1
NCT00679341	Hoffmann-La Roche	Breast Cancer	2008/9/1	Phase 2
NCT01526369	Cancer Trials Ireland	Metastatic Breast Cancer	2012/1/1	Phase 3
NCT01641939	Hoffmann-La Roche	Gastric Cancer	2012/9/3	Phase 2 Phase 3
NCT03521245	OmicsWay Corp. Oncobox Ltd., Russia Vitamed LLC, Russia Republican Oncological Dispensary of Karelia Republic, Russia	HER2-positive Breast Cancer	2017/10/1	
NCT04420598	MedSIR Daiichi Sankyo, Inc.	Advanced Breast Cancer HER2-positive Breast Cancer Brain Metastases Leptomeningeal Metastasis	2020/5/25	Phase 2
NCT00411788	Yale University Genentech, Inc.	Breast Cancer	2006/12/1	Phase 2
NCT00896376	Centre Antoine Lacassagne	Breast Cancer	2005/12/1	Not Applicable
NCT00971737	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI)	Breast Cancer	2009/7/1	Phase 2
NCT03425656	AryoGen Pharmed Co.	Malignant Neoplasm of Breast	2016/7/9	Phase 3
NCT00440622	Hellenic Oncology Research Group University Hospital of Crete	Breast Cancer	April 2003	Phase 3
NCT02578368	Krankenhaus Nordwest German Research Foundation Arbeitsgemeinschaft für Internistische Onkologie	Gastric Cancer	2016/2/1	Phase 3
NCT00391092	Hoffmann-La Roche	Breast Cancer	2006/9/1	Phase 3
NCT00250874	Zeneus Pharma	Metastatic Breast Cancer	2003/12/1	Phase 2
NCT01106898	University of Nebraska National Cancer Institute (NCI)	Stage IA Breast Cancer Stage IB Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer	2010/3/1	Phase 2
NCT01276041	Memorial Sloan Kettering Cancer Center Genentech, Inc. University of Pennsylvania	Breast Cancer	2011/1/5	Phase 2
NCT01971515	EMD Serono	Solid Tumor	2013/12/13	Phase 1
NCT04962425	Peking University Third Hospital	Cardiac Toxicity Antitumor Drugs Breast Cancer	2021/1/8	

NCT01196390	National Cancer Institute (NCI) NRG Oncology	Esophageal Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Stage IB Esophageal Cancer AJCC v7 Stage IIA Esophageal Cancer AJCC v7 Stage IIB Esophageal Cancer AJCC v7 Stage IIIA Esophageal Cancer AJCC v7 Stage IIIB Esophageal Cancer AJCC v7	2010/12/30	Phase 3
NCT02345772	Western Regional Medical Center	HER2-positive Breast Cancer ER-positive Breast Cancer	2014/7/1	Phase 1 Phase 2
NCT01880385	Association Tunisienne de lutte Contre le Cancer Hoffmann-La Roche Sanofi	Inflammatory Breast Cancer	2011/3/1	Phase 1
NCT00615602	Hellenic Oncology Research Group University Hospital of Crete	Breast Cancer	2004/10/1	Phase 3
NCT01041404	Hoffmann-La Roche Chugai Pharmaceutical	Gastric Cancer	2005/9/1	Phase 3
NCT01746771	Hanmi Pharmaceutical Company Limited National OncoVenture	HER-2 Positive Advanced Gastric Cancer	2012/11/1	Phase 1 Phase 2
NCT01170143	Fudan University Hoffmann-La Roche	Breast Cancer	2009/8/1	Phase 2
NCT03101748	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Breast Inflammatory Carcinoma Locally Advanced Breast Carcinoma Metastatic Breast Carcinoma Stage III Breast Cancer AJCC v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7	2018/1/29	Phase 1 Phase 2
NCT05034887	National Cancer Center Hospital East Daiichi Sankyo Co., Ltd.	Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	2021/9/1	Phase 2
NCT00191451	Eli Lilly and Company	Breast Cancer	April 2004	Phase 2
NCT02731313	Hoffmann-La Roche	Gastric Cancer, Gastroesophageal Junction Cancer	2012/7/1	
NCT02657343	Dana-Farber Cancer Institute Novartis	Breast Cancer	2016/3/9	Phase 1 Phase 2
NCT00005926	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Pancreatic Cancer Pancreatic Neoplasm	2000/6/1	Phase 2
NCT02260531	Dana-Farber Cancer Institute Exelixis Genentech, Inc.	Breast Cancer Brain Tumor - Metastatic	2014/11/1	Phase 2
NCT03329378	Icahn School of Medicine at Mount Sinai	Locally Advanced Breast Cancer	2019/1/30	Phase 2
NCT02654119	University of Nebraska National Cancer Institute (NCI)	HER2 Positive Breast Carcinoma Stage I Breast Cancer AJCC v7 Stage IA Breast Cancer AJCC v7 Stage IB Breast Cancer AJCC v7 Stage II Breast Cancer AJCC v6 and v7 Stage IIA Breast Cancer AJCC v6 and v7 Stage IIB Breast Cancer AJCC v6 and v7	2015/12/11	Phase 2
NCT01613482	Centre Oscar Lambret	Breast Cancer Metastasis Sur-expressing Her2-neu	2007/10/1	Phase 3
NCT00433095	Ludwig-Maximilians - University of Munich Pierre Fabre Laboratories	Carcinoma Breast Stage IV		Phase 2

NCT01817452	West German Study Group Roche Pharma AG	Breast Cancer	2014/3/1	Phase 2
NCT00005635	Genentech, Inc. National Cancer Institute (NCI)	Breast Cancer	2000/1/1	Phase 2
NCT01875666	UNC Lineberger Comprehensive Cancer Center Genentech, Inc. Susan G. Komen Breast Cancer Foundation GlaxoSmithKline	Breast Neoplasms	2013/8/5	Early Phase 1
NCT03756064	Zhejiang Cancer Hospital	Breast Cancer Neoplasm, Breast Breast Diseases	2019/8/1	Not Applicable
NCT04499924	Seagen Inc.	Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Esophageal Adenocarcinoma	2021/3/22	Phase 2 Phase 3
NCT00509769	Genentech, Inc.	Metastatic Breast Cancer	2007/7/1	Phase 2
NCT04585958	National Cancer Institute (NCI)	Endometrial Serous Adenocarcinoma Metastatic Malignant Solid Neoplasm Unresectable Malignant Solid Neoplasm	2021/1/4	Phase 1
NCT00458237	Beth Israel Deaconess Medical Center Novartis Pharmaceuticals Dana-Farber Cancer Institute	Breast Cancer	April 2007	Phase 1 Phase 2
NCT04419181	University of Rochester	HER2-positive Breast Cancer	2022/6/1	Phase 2
NCT04208178	Novartis Pharmaceuticals Novartis	Advanced HER2+ Breast Cancer	2020/7/16	Phase 3
NCT02144012	Hoffmann-La Roche	Metastatic Breast Cancer	2014/6/1	Phase 3
NCT00847171	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI)	Breast Cancer	2008/12/1	Phase 2
NCT02445586	Hoffmann-La Roche	Breast Cancer	2015/8/17	Phase 4
NCT01730833	City of Hope Medical Center National Cancer Institute (NCI)	HER2-positive Breast Cancer Recurrent Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Breast Adenocarcinoma Inflammatory Breast Carcinoma	2013/7/17	Phase 2
NCT04733118	MedSIR Hoffmann-La Roche	Early Breast Cancer	April 2021	Phase 2
NCT01513083	Hoffmann-La Roche	Breast Cancer	2012/2/1	Phase 1
NCT00003881	Eastern Cooperative Oncology Group National Cancer Institute (NCI)	Lung Cancer	1999/5/1	Phase 2
NCT04014075	Daiichi Sankyo, Inc. AstraZeneca	Adenocarcinoma Gastric Stage IV With Metastases Adenocarcinoma - GEJ	2019/7/30	Phase 2
NCT03043313	Seagen Inc. National Cancer Institute (NCI) Academic and Community Cancer Research United	Metastatic Colorectal Adenocarcinoma	2017/6/23	Phase 2
NCT00681993	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Breast Cancer Research Foundation	Breast Cancer	April 2008	Not Applicable

NCT03820141	The Methodist Hospital Research Institute AstraZeneca	Breast Cancer	2020/3/3	Phase 2
NCT00086957	City of Hope Medical Center National Cancer Institute (NCI)	Breast Cancer	2004/1/1	Phase 1 Phase 2
NCT03644186	International Breast Cancer Study Group Pfizer Hoffmann-La Roche	Breast Cancer Estrogen Receptor Positive Tumor HER2-positive Breast Cancer	April 16, 2019	Phase 2
NCT00533936	Instituto Nacional de Cancerologia, Columbia National Cancer Institute (NCI)	Breast Cancer	2006/9/1	Phase 2
NCT04917900	West China Hospital	Breast Cancer	2020/12/1	Phase 2
NCT04675827	Jules Bordet Institute Breast International Group Hoffmann-La Roche International Drug Development Institute Institut Curie	HER2-positive Breast Cancer ER-Negative Breast Cancer PR-Negative Breast Cancer Node-negative Breast Cancer	2021/6/1	Phase 2
NCT00084513	Fox Chase Cancer Center National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	2004/8/1	Phase 1
NCT02510781	Hospital Affiliated to Military Medical Science, Beijing	Breast Neoplasms	2015/1/1	Phase 2
NCT00796978	Cynthia Owusu, MD National Cancer Institute (NCI) Case Comprehensive Cancer Center	Breast Cancer	2008/11/11	Phase 2
NCT00434031	National Cancer Institute, Naples	Breast Cancer	2007/9/1	Phase 2
NCT02307227	Centro di Riferimento Oncologico - Aviano	Breast Neoplasms	April 2006	Phase 2
NCT01097460	Merrimack Pharmaceuticals	Breast Neoplasms	April 2010	Phase 1
NCT01265927	Indiana University Breast Cancer Research Foundation Geron Corporation	Breast Neoplasms	2011/1/1	Phase 1
NCT02999672	Hoffmann-La Roche	Bladder Cancer Pancreas Cancer Cholangiocellular Carcinoma	2016/12/23	Phase 2
NCT02167854	Memorial Sloan Kettering Cancer Center Novartis	Breast Cancer	2014/6/16	Phase 1
NCT00829166	Hoffmann-La Roche	Breast Cancer	2009/2/1	Phase 3
NCT02586025	Hoffmann-La Roche	Breast Cancer	2016/3/14	Phase 3
NCT02000596	Katherine Tkaczuk Genentech, Inc. University of Maryland, Baltimore	Metastatic Breast Cancer	2014/1/1	Phase 2
NCT00039455	National Cancer Institute (NCI)	HER2-positive Breast Cancer Male Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer	April 2002	Phase 1
NCT03595592	Fondazione Michelangelo Hoffmann-La Roche	Invasive Breast Cancer	2018/9/7	Phase 3
NCT04958486	The University of Texas Health Science Center, Houston	Fossa Ependymoma	2021/7/8	Early Phase 1
NCT04759248	SOLTI Breast Cancer Research Group Roche Pharma AG	Breast Cancer	2021/3/15	Phase 2
NCT04172259	Sun Yat-sen University First Affiliated Hospital, Sun Yat-Sen University Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Breast Cancer Neoadjuvant Chemotherapy	2019/1/10	Phase 2

NCT00199212	Jules Bordet Institute	Carcinoma Breast Stage IV	2003/10/1	Phase 1
NCT00842998	Azienda Ospedaliera Ordine Mauriziano di Torino	Metastatic Breast Cancer	2009/2/1	Phase 2
NCT01359397	The Netherlands Cancer Institute	Metastatic Gastric Cancer Adenocarcinoma of the Gastro-oesophageal Junction	2011/3/1	Phase 2
NCT00875979	Hoffmann-La Roche Roche Pharma AG	Metastatic Breast Cancer	2009/5/1	Phase 1 Phase 2
NCT02019277	Hoffmann-La Roche	Breast Cancer	2013/12/5	Phase 3
NCT02314481	University College, London Hoffmann-La Roche	Non-small Cell Lung Cancer	2017/5/12	Phase 2
NCT01828736	Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie Roche Pharma AG	Recurrent Bladder Cancer Stage IV Bladder Cancer Transitional Cell Carcinoma of the Bladder	2004/2/9	Phase 2
NCT02594761	Mylan Pharmaceuticals Mylan GmbH	Healthy	2013/8/1	Phase 1
NCT04425018	Dana-Farber Cancer Institute MacroGenics Translational Breast Cancer Research Consortium	Breast Cancer Stage II Breast Cancer Stage III Breast Cancer HER2-positive Breast Cancer	2020/7/13	Phase 2
NCT01042925	Sanofi	Breast Cancer Breast Neoplasms	2010/2/1	Phase 1 Phase 2
NCT00513292	National Cancer Institute (NCI)	HER2+Neu Positive Stage IA Breast Cancer Stage IB Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer	2007/7/1	Phase 3
NCT00429299	GlaxoSmithKline	Neoplasms, Breast	2006/8/1	Phase 2
NCT00453635	Hellenic Oncology Research Group University Hospital of Crete	Breast Cancer	2003/12/1	Phase 2
NCT01485926	Cancer Trials Ireland	Breast Cancer	2010/10/1	Phase 2
NCT01548677	European Organisation for Research and Treatment of Cancer - EORTC Hoffmann-La Roche Janssen Diagnostics, LLC SUCCESS UNICANCER	Breast Cancer Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Circulating Tumor Cells	April 2013	Phase 2
NCT00004883	National Cancer Institute (NCI)	Recurrent Non-small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer	2000/2/1	Phase 2
NCT00068341	Jonsson Comprehensive Cancer Center Aventis Pharmaceuticals Genentech, Inc.	Breast Cancer	2003/7/1	Phase 2
NCT01120184	Hoffmann-La Roche Genentech, Inc.	Breast Cancer	2010/7/31	Phase 3
NCT02390427	Dana-Farber Cancer Institute Genentech, Inc.	Metastatic Breast Cancer Recurrent Breast Cancer	April 2015	Phase 1
NCT00372424	Pfizer	Breast Cancer	2006/12/1	Phase 1
NCT00768859	The Netherlands Cancer Institute	Breast Cancer HER2 Positive	2008/9/1	Phase 2
NCT03765983	Dana-Farber Cancer Institute Kazia Therapeutics Limited	Breast Cancer	2019/2/11	Phase 2
NCT03161353	MedSIR	Breast Cancer	2017/6/26	Phase 2
NCT00004163	Dana-Farber Cancer Institute National Cancer Institute (NCI) Genentech, Inc.	Head and Neck Cancer	1999/10/1	Phase 2

NCT01670877	Washington University School of Medicine Puma Biotechnology, Inc. United States Department of Defense	Breast Neoplasms	2012/12/11	Phase 2
NCT00428922	Bhuvanewari Ramaswamy Genentech, Inc. Case Comprehensive Cancer Center University of Pittsburgh Ohio State University Comprehensive Cancer Center	Breast Cancer	2007/6/14	Phase 2
NCT02030561	National University Hospital, Singapore National University, Singapore	Breast Cancer Gastric Cancer	2014/1/1	Phase 1 Phase 2
NCT04215159	Jin-Hee Ahn Asan Medical Center	HER-2 Protein Overexpression HER-2 Gene Amplification	2019/12/30	Phase 2
NCT01894711	Maastricht University Medical Center	Breast Cancer	2010/5/1	
NCT04383275	Fudan University	Breast Cancer	2020/5/15	Phase 2
NCT02379585	Western Regional Medical Center	HER2-positive Breast Cancer	2013/1/1	Phase 1 Phase 2
NCT04908813	Shanghai Henlius Biotech	Gastric Cancer	2021/10/1	Phase 2
NCT01940497	Hoffmann-La Roche	Breast Cancer	2013/11/15	Phase 3
NCT00393783	Memorial Sloan Kettering Cancer Center	Breast Cancer	2006/5/1	Phase 1
NCT00398437	Jules Bordet Institute National Cancer Institute (NCI)	Breast Cancer Metastatic Cancer	2006/9/1	Not Applicable
NCT04629846	Qilu Pharmaceutical Co., Ltd.	Breast Cancer	2020/11/1	Phase 3
NCT04609540	Shandong Cancer Hospital and Institute	HER2-positive Breast Cancer Metastatic Breast Cancer	2021/1/1	
NCT00146042	University of Michigan Rogel Cancer Center Genentech, Inc.	HER-2 Positive Metastatic Breast Cancer	1999/3/1	Phase 2
NCT01419197	Hoffmann-La Roche	Breast Cancer	2011/9/1	Phase 3
NCT02066532	Dawn L. Hershman Incyte Corporation National Cancer Institute (NCI) Columbia University	Metastatic Breast Cancer Breast Carcinoma HER-2 Positive Breast Cancer	2014/6/1	Phase 1 Phase 2
NCT02901301	Yonsei University	Gastric Cancer	2017/2/6	Phase 1 Phase 2
NCT02040935	Hoffmann-La Roche	Breast Cancer	2014/2/21	Phase 3
NCT01966471	Hoffmann-La Roche	Breast Cancer	2014/1/31	Phase 3
NCT00004013	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Breast Cancer	1999/1/1	Phase 2
NCT01204372	Institut du Cancer de Montpellier - Val d'Aurelle	Metastatic Pancreatic Adenocarcinoma	2010/6/1	Phase 2
NCT01594177	German Breast Group Boehringer Ingelheim	Unilateral HER2 Positive Breast Cancer	2012/5/1	Phase 2
NCT04307329	The Netherlands Cancer Institute AstraZeneca	Breast Cancer	2021/3/23	Phase 2

NCT03364348	George W. Sledge Jr. National Cancer Institute (NCI) Stanford University	HER2 Positive Breast Carcinoma Recurrent Breast Carcinoma Stage III Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer	2017/10/30	Phase 1
NCT04024462	Hoffmann-La Roche	HER2-positive Early Breast Cancer	2020/2/5	Phase 3
NCT01084863	Celltrion	Metastatic Breast Cancer	2010/2/1	Phase 1 Phase 2
NCT01557764	Washington University School of Medicine	Breast Neoplasms	2012/9/1	Phase 2
NCT02336984	H. Lee Moffitt Cancer Center and Research Institute	Breast Cancer	2014/6/1	Phase 1 Phase 2
NCT04993014	AC Camargo Cancer Center	Breast Neoplasms HER2-positive Breast Cancer Circulating Tumor Cell	2021/3/1	Phase 2
NCT00005970	National Cancer Institute (NCI) Cancer and Leukemia Group B Eastern Cooperative Oncology Group Canadian Cancer Trials Group Southwest Oncology Group	Breast Adenocarcinoma HER2 Positive Breast Carcinoma Stage IA Breast Cancer AJCC v7 Stage IB Breast Cancer AJCC v7 Stage IIA Breast Cancer AJCC v6 and v7 Stage IIB Breast Cancer AJCC v6 and v7 Stage IIIA Breast Cancer AJCC v7	2000/5/19	Phase 3
NCT02638428	Samsung Medical Center Ministry of Health, Republic of Korea	Relapsed Pediatric Solid Tumor Refractory Pediatric Solid Tumor Relapsed Pediatric AML Refractory Pediatric AML	2015/12/1	Phase 2
NCT02627274	Hoffmann-La Roche	Solid Tumor Breast Cancer Cancer of Head and Neck	2015/12/7	Phase 1
NCT00398489	Technische Universität München National Cancer Institute (NCI)	Breast Cancer	2006/10/1	Phase 2
NCT00927589	Genentech, Inc.	Solid Cancers	2009/7/1	Phase 1
NCT01873833	University of Southern California National Cancer Institute (NCI)	HER2-positive Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer	2013/7/29	Phase 2
NCT00270894	Accelerated Community Oncology Research Network Aventis Pharmaceuticals	Breast Neoplasm	2005/11/1	Phase 2
NCT00450892	European Organisation for Research and Treatment of Cancer - EORTC GlaxoSmithKline	Breast Cancer	2007/2/1	Phase 1 Phase 2
NCT00006089	National Cancer Institute (NCI) Gynecologic Oncology Group	Endometrial Adenocarcinoma ERBB2 Gene Amplification Recurrent Uterine Corpus Carcinoma Stage III Uterine Corpus Cancer AJCC v7 Stage IV Uterine Corpus Cancer AJCC v7	2000/9/18	Phase 2

NCT03878524	OHSU Knight Cancer Institute Oregon Health and Science University	<p>Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Anatomic Stage IV Breast Cancer AJCC v8 Anemia Ann Arbor Stage III Hodgkin Lymphoma Ann Arbor Stage III Non-Hodgkin Lymphoma Ann Arbor Stage IIIA Hodgkin Lymphoma Ann Arbor Stage IIIB Hodgkin Lymphoma Ann Arbor Stage IV Hodgkin Lymphoma Ann Arbor Stage IV Non-Hodgkin Lymphoma Ann Arbor Stage IVA Hodgkin Lymphoma Ann Arbor Stage IVB Hodgkin Lymphoma Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Castration-Resistant Prostate Carcinoma Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Hematopoietic and Lymphoid Cell Neoplasm Locally Advanced Pancreatic Adenocarcinoma Metastatic Breast Carcinoma Metastatic Malignant Solid Neoplasm Metastatic Pancreatic Adenocarcinoma Myelodysplastic+Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable Primary Myelofibrosis Prognostic Stage IV Breast Cancer AJCC v8 Recurrent Acute Lymphoblastic Leukemia Recurrent Acute Myeloid Leukemia Recurrent Chronic Lymphocytic Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent Hematologic Malignancy Recurrent Hodgkin Lymphoma Recurrent Myelodysplastic Syndrome Recurrent Myelodysplastic+Myeloproliferative Neoplasm Recurrent Myeloproliferative Neoplasm Recurrent Non-Hodgkin Lymphoma Recurrent Plasma Cell Myeloma Recurrent Small Lymphocytic Lymphoma Refractory Acute Lymphoblastic Leukemia Refractory Acute Myeloid Leukemia Refractory Chronic Lymphocytic Leukemia Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive Refractory Chronic Myelomonocytic Leukemia Refractory Hematologic Malignancy Refractory Hodgkin Lymphoma Refractory Malignant Solid</p>	April 1, 2020	Phase 1
-------------	---	---	---------------	---------

		Neoplasm Refractory Myelodysplastic Syndrome Refractory Myelodysplastic+Myeloproliferative Neoplasm Refractory Non-Hodgkin Lymphoma Refractory Plasma Cell Myeloma Refractory Primary Myelofibrosis Refractory Small Lymphocytic Lymphoma Stage II Pancreatic Cancer AJCC v8 Stage IIA Pancreatic Cancer AJCC v8 Stage IIB Pancreatic Cancer AJCC v8 Stage III Pancreatic Cancer AJCC v8 Stage IV Pancreatic Cancer AJCC v8 Stage IV Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8 Stage IVB Prostate Cancer AJCC v8 Unresectable Pancreatic Adenocarcinoma		
NCT00047255	Jonsson Comprehensive Cancer Center	Breast Cancer	2002/5/1	Phase 3
NCT04108858	National Cancer Institute (NCI)	Anatomic Stage IV Breast Cancer AJCC v8 HER2-Positive Breast Carcinoma Metastatic Breast Carcinoma	2019/12/6	Phase 1 Phase 2
NCT04538742	AstraZeneca Daiichi Sankyo Company, Limited	Metastatic Breast Cancer	2020/12/28	Phase 1 Phase 2
NCT00803556	Bristol-Myers Squibb	Solid Tumor Breast Cancer	2006/1/1	Phase 1
NCT02614794	Seagen Inc.	HER2 Positive Breast Cancer	2016/1/28	Phase 2
NCT02735798	Pamela Munster University of California, San Francisco	Brain Metastases Documented Her2 Overexpression Advanced Solid Tumor Neurologically Stable	April 2016	Early Phase 1
NCT04986579	Dana-Farber Cancer Institute Paxman Coolers Limited AZ+Daiichi	Metastatic Breast Cancer Chemotherapy-induced Alopecia	2021/11/30	Phase 2
NCT03742102	AstraZeneca	Triple Negative Breast Neoplasms	2018/12/21	Phase 1 Phase 2
NCT00005033	Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI)	Sarcoma	1999/12/1	Phase 2
NCT03135171	University of Michigan Rogel Cancer Center	Breast Cancer	2017/7/26	Phase 1

NCT03304080	Icahn School of Medicine at Mount Sinai Herbert Irving Comprehensive Cancer Center Weill Medical College of Cornell University NYU Langone Health	Breast Neoplasms Breast Diseases	2017/12/20	Phase 1 Phase 2
NCT00470847	Nancy Lin, MD Brigham and Women's Hospital Breast Cancer Research Foundation GlaxoSmithKline Dana-Farber Cancer Institute	Breast Cancer Brain Metastases	April 2007	Phase 1
NCT02598310	Osaka Medical College	Breast Cancer Estrogen Receptor Negative Neoplasm HER-2 Positive Breast Cancer	2015/11/1	Phase 2
NCT02213744	Merrimack Pharmaceuticals	Breast Cancer HER2 Positive Breast Cancer	2014/7/1	Phase 2 Phase 3
NCT02214004	Gangnam Severance Hospital Seoul National University Hospital Severance Hospital Samsung Medical Center Asan Medical Center	Breast Cancer	2015/3/1	Phase 2
NCT01254136	Incyte Corporation	Breast Cancer	2010/10/1	Phase 1 Phase 2
NCT04175171	Genor Biopharma Co., Ltd.	Metastatic Breast Cancer	2011/11/7	Phase 1
NCT00004925	Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI)	Breast Cancer	1999/8/1	Phase 1 Phase 2
NCT00543504	M.D. Anderson Cancer Center	Advanced Cancer	2007/10/10	Phase 1
NCT04464967	NKGen Biotech, Inc.	Advanced Solid Tumor Metastatic Cancer HER2-positive Breast Cancer HER2-positive Gastric Cancer HER-2 Protein Overexpression Esophageal Cancer Ovarian Cancer Endometrium Cancer Bladder Cancer Pancreatic Cancer Colorectal Cancer Non Small Cell Lung Cancer EGF-R Positive Non-Small Cell Lung Cancer Head and Neck Squamous Cell Carcinoma Triple Negative Breast Cancer Cervical Cancer Sarcoma	2021/3/1	Phase 1 Phase 2
NCT01950182	Sun Yat-sen University	Breast Cancer	2013/9/16	Phase 3
NCT01904903	Medstar Health Research Institute Genentech, Inc.	HER2 Positive Breast Cancer Left Ventricular Function Systolic Dysfunction	2013/10/1	Phase 2
NCT04509596	Dizal Pharmaceuticals	Breast Cancer Metastatic	2020/9/21	Phase 1
NCT00429247	University Hospital of Crete	Breast Cancer	2003/2/1	Phase 2
NCT01285466	Novartis Pharmaceuticals Novartis	Metastatic or Locally Advanced Solid Tumors	2011/1/1	Phase 1
NCT01816594	Novartis Pharmaceuticals Breast International Group German Breast Group SOLTI Breast Cancer Research Group Novartis	HER2-positive Newly Diagnosed, Primary Breast Cancer	2013/9/3	Phase 2
NCT02738970	Hoffmann-La Roche	Early Breast Cancer	2016/6/23	Phase 1
NCT01351350	Millennium Pharmaceuticals, Inc. Takeda	Advanced Solid Malignancies Hematologic Malignancies	2011/2/28	Phase 1

NCT02291289	Hoffmann-La Roche	Colorectal Cancer	April 17, 2015	Phase 2
NCT04961307	Peking University Third Hospital	Cardiotoxicity Antitumor Drugs Breast Cancer Trastuzumab	2019/7/5	
NCT00399529	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Cancer Society, Inc. Avon Foundation Cancer Treatment Research Foundation The Commonwealth Fund United States Department of Defense Genentech, Inc.	Breast Neoplasms	2006/9/1	Phase 2
NCT03125928	Fox Chase Cancer Center Genentech, Inc.	HER2-positive Breast Cancer	2017/6/13	Phase 2
NCT03505710	Daiichi Sankyo, Inc. Daiichi Sankyo Co., Ltd. AstraZeneca	Non-Small Cell Lung Cancer	2018/5/21	Phase 2
NCT04290793	Hebei Medical University Fourth Hospital	Breast Cancer	2020/3/1	Phase 2 Phase 3
NCT01300962	UNC Lineberger Comprehensive Cancer Center Novartis Pharmaceuticals	Metastatic Breast Cancer	2011/8/1	Phase 1
NCT02571530	Northwell Health	Neoplasm Metastasis	2015/9/1	Phase 1
NCT02925234	The Netherlands Cancer Institute Amgen AstraZeneca Bayer Bristol-Myers Squibb Novartis Roche Pharma AG Merck Sharp & Dohme Corp. Boehringer Ingelheim Ipsen Eisai Inc. Pfizer Clovis Oncology, Inc. Eli Lilly and Company Janssen, LP	Cancer Tumors Neoplasm Neoplasia	2016/8/1	Phase 2
NCT05063786	Spanish Breast Cancer Research Group International Breast Cancer Study Group Breast International Group Novartis Pharmaceuticals	Advanced Breast Cancer	2021/9/1	Phase 3
NCT00386685	Sanofi	Breast Neoplasms	2006/7/1	Phase 2
NCT02658734	Hoffmann-La Roche	HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer	2016/11/1	Phase 4
NCT00216047	Hoosier Cancer Research Network Novartis Pharmaceuticals Walther Cancer Institute	Breast Cancer	2005/1/1	Phase 1 Phase 2
NCT04439110	National Cancer Institute (NCI)	Advanced Lymphoma Advanced Malignant Solid Neoplasm Hematopoietic and Lymphoid Cell Neoplasm Refractory Lymphoma Refractory Malignant Solid Neoplasm Refractory Plasma Cell Myeloma	2015/8/12	Phase 2
NCT00189579	ARCAGY+ GINECO GROUP Hoffmann-La Roche	Ovarian Cancer		Phase 2
NCT01273610	City of Hope Medical Center GlaxoSmithKline Novartis	Breast Neoplasms HER2+Neu Positive Geriatric Health Services	April 20, 2011	Phase 2

NCT00309556	Austrian Breast & Colorectal Cancer Study Group Amgen Ebewe Pharma GmbH Hoffmann-La Roche Sanofi	Breast Cancer	2005/2/1	Phase 3
NCT03238495	Qamar Khan University of Kansas Medical Center	HER2-positive Breast Cancer	2017/8/2	Phase 2
NCT00817362	Infinity Pharmaceuticals, Inc.	Breast Cancer HER2 Positive Breast Cancer Metastatic Breast Cancer Cancer of the Breast	2009/3/1	Phase 2
NCT04482309	AstraZeneca Daiichi Sankyo Co., Ltd.	Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Rare Tumors	2020/8/18	Phase 2
NCT04120246	University of Washington National Cancer Institute (NCI) Veana Therapeutics, Inc.	Anatomic Stage IV Breast Cancer AJCC v8 HER2 Positive Breast Carcinoma Metastatic Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8 Refractory Breast Carcinoma	April 8, 2020	Phase 1
NCT04556773	AstraZeneca Daiichi Sankyo Company, Limited	Metastatic Breast Cancer	2020/12/17	Phase 1
NCT01503905	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Breast Cancer Nos Premenopausal	2011/12/1	Not Applicable
NCT05041842	UNICANCER Seagen Inc. ARCAGY+ GINECO GROUP	Metastatic Breast Cancer With a Isolated Brain Progression	2021/9/30	Phase 2
NCT00496808	M.D. Anderson Cancer Center	Ductal Carcinoma In Situ	2005/3/1	Not Applicable
NCT00928330	Genentech, Inc.	Metastatic Breast Cancer	2009/7/1	Phase 1
NCT00303108	US Oncology Research Ortho Biotech, Inc. Tibotec Pharmaceutical Limited	Metastatic Breast Cancer	2005/12/1	Phase 2
NCT00169104	Dartmouth-Hitchcock Medical Center Amgen	Metastatic Breast Cancer	2002/7/1	Phase 2 Phase 3
NCT01928615	Hoffmann-La Roche	Breast Cancer	2013/9/1	Phase 2
NCT00550771	Merck Sharp & Dohme Corp.	Breast Neoplasm	2007/7/16	Phase 2
NCT01602406	Novartis Pharmaceuticals Novartis	Advanced HER2-positive Breast Cancer or Gastric Cancer	2012/9/21	Phase 1
NCT04819971	The First Affiliated Hospital of Zhengzhou University	Stomach Cancer	2021/12/1	Phase 2
NCT04294628	National Cancer Institute (NCI)	HER2-Positive Breast Carcinoma Metastatic Malignant Solid Neoplasm Refractory Malignant Solid Neoplasm Unresectable Malignant Solid Neoplasm	2020/7/14	Phase 1
NCT01679743	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Breast Cancer Lung Neoplasms Breast Neoplasms Lung Cancer	2012/8/29	Phase 2
NCT00088985	UNC Lineberger Comprehensive Cancer Center National Cancer Institute (NCI) Susan G. Komen Breast Cancer Foundation	Breast Cancer	2004/1/1	Phase 2

NCT03925233	Xijing Hospital	Breast Cancer Organoids	2019/1/2	
NCT02805829	Xuzhou Medical University	Gastric Cancer	2017/1/1	Phase 1 Phase 2
NCT00667251	Novartis Pharmaceuticals NCIC Clinical Trials Group Novartis	Breast Cancer	2008/10/7	Phase 3
NCT00068757	European Organisation for Research and Treatment of Cancer - EORTC	Breast Cancer	2003/8/1	Phase 1
NCT02658084	University of Miami Genentech, Inc.	Breast Cancer Metastatic Breast Cancer	April 12, 2017	Phase 1 Phase 2
NCT04997798	First Affiliated Hospital of Zhejiang University	Breast Cancer Estrogen Receptor Positive Tumor HER2-positive Breast Cancer	2021/12/1	Phase 2
NCT02402712	Hoffmann-La Roche	Breast Cancer	2015/5/6	Phase 3
NCT03297606	Canadian Cancer Trials Group AstraZeneca Bristol-Myers Squibb Hoffmann-La Roche Pfizer	Lymphoma, Non-Hodgkin Multiple Myeloma Advanced Solid Tumors	2017/10/6	Phase 2
NCT01690325	West German Study Group Roche Pharma AG Sanofi	Breast Cancer	2012/9/1	Phase 2
NCT03334617	AstraZeneca	Non-Small Cell Lung Cancer	2017/12/18	Phase 2
NCT03845270	Intergroupe Francophone de Cancerologie Thoracique	Non Small Cell Lung Cancer Metastatic Non Small Cell Lung Cancer Stage III HER2 Gene Mutation	2019/5/17	Phase 2
NCT01998906	Hoffmann-La Roche	Breast Cancer	2002/5/1	Phase 3
NCT03199300	University Medical Center Groningen	Toxicity Due to Chemotherapy Cardiovascular Morbidity Cancer, Treatment-Related	2017/12/12	
NCT01702558	Hoffmann-La Roche	Breast Cancer Gastric Cancer	2012/12/3	Phase 2
NCT00258349	National Cancer Institute (NCI)	Breast Cancer Male Breast Cancer Recurrent Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer	2006/8/1	Phase 1 Phase 2
NCT00944047	University of Kansas Medical Center Celgene Corporation	Breast Cancer	2009/7/1	Phase 2
NCT02132949	Hoffmann-La Roche	Breast Cancer	2014/7/14	Phase 2
NCT04639219	AstraZeneca Daiichi Sankyo Co., Ltd.	Advanced Solid Tumors With HER2 Mutation, eg: Colorectal, Urothelial, Gastric, Hepatobiliary, Endometrial, Melanoma, Ovarian, Cervical, Salivary Gland, Pancreatic, Breast	2020/12/30	Phase 2
NCT00404066	George Albert Fisher GlaxoSmithKline Sanofi Stanford University	Breast Cancer Metastatic Breast Cancer	2006/10/1	Phase 2
NCT01428414	Zhimin Shao Roche Pharma AG Fudan University	HER-2 Positive Breast Cancer	2011/8/1	Phase 2
NCT00412412	Biogen	Breast Cancer	2007/12/1	Phase 1
NCT01835236	Swiss Group for Clinical Cancer Research	Metastatic Breast Cancer	2013/3/3	Phase 2
NCT01077648	GlaxoSmithKline	Cancer	2010/2/1	
NCT04589845	Hoffmann-La Roche	Solid Tumors	2021/1/18	Phase 2
NCT00485979	Sanofi	Breast Neoplasms	2007/6/1	Phase 2

NCT00148876	German Breast Group Hoffmann-La Roche	Breast Cancer	2003/9/1	Phase 3
NCT03418558	Fondazione del Piemonte per l'Oncologia	Metastatic Colorectal Cancer	2015/7/8	Phase 2
NCT04281576	NovoCure GmbH Zai Lab (Shanghai) Co., Ltd. NovoCure Ltd.	Gastric Cancer GastroEsophageal Cancer	2019/12/19	Not Applicable
NCT01301729	Hoffmann-La Roche	Breast Cancer	2011/3/1	Phase 4
NCT01969643	Seagen Inc.	Breast Cancer	2013/10/22	Phase 1
NCT03013881	United BioPharma Tri-Service General Hospital	Breast Neoplasm	2018/3/5	Phase 1
NCT01401959	SCRI Development Innovations, LLC Eisai Inc.	Metastatic Breast Cancer	2011/9/23	Phase 2
NCT00103233	Southwest Oncology Group National Cancer Institute (NCI)	Breast Cancer	2004/12/1	Phase 3
NCT02162667	Celltrion Nippon Kayaku Co., Ltd.	HER2-positive Carcinoma of Breast	2014/6/1	Phase 3
NCT01104935	Comprehensive Support Project for Oncology Research	Breast Cancer	2009/10/28	Phase 3
NCT01235897	University of California, San Francisco Merck Sharp & Dohme Corp.	Advanced Solid Tumors Tumors Cancer	2011/3/1	Phase 1
NCT00126607	National Cancer Institute (NCI)	High-grade Salivary Gland Mucoepidermoid Carcinoma Recurrent Salivary Gland Cancer Salivary Gland Acinic Cell Tumor Salivary Gland Adenocarcinoma Salivary Gland Poorly Differentiated Carcinoma Stage IVA Salivary Gland Cancer Stage IVB Salivary Gland Cancer Stage IVC Salivary Gland Cancer	2005/7/1	Phase 2
NCT00567554	German Breast Group AGO Study Group	Breast Cancer	2007/10/1	Phase 3
NCT02689921	Midwestern Regional Medical Center	Breast Neoplasms	April 2016	Phase 2
NCT02289833	Hoffmann-La Roche	Non-Small Cell Lung Cancer	2014/12/15	Phase 2
NCT04547907	Henan Cancer Hospital	Breast Cancer,Her2 Positive	2020/9/18	Phase 3
NCT04512261	Reva Basho Merck Sharp & Dohme Corp. Seagen Inc. Cedars-Sinai Medical Center	Breast Cancer Brain Metastases HER2-positive Breast Cancer CNS Disease	2021/10/1	Phase 1 Phase 2
NCT00288002	German Breast Group National Cancer Institute (NCI)	Breast Cancer	2005/1/1	Phase 3
NCT00367250	Medical University of Vienna	Metastatic Breast Cancer	2006/7/1	Phase 1
NCT03094052	University of California, San Francisco Puma Biotechnology, Inc.	HER2-positive Breast Cancer Breast Adenocarcinoma Stage II Breast Cancer AJCC v6 and v7 Stage IIA Breast Cancer AJCC v6 and v7 Stage IIB Breast Cancer AJCC v6 and v7 Stage III Breast Cancer AJCC v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7	2018/10/9	Phase 2
NCT03084939	Hoffmann-La Roche	Breast Cancer	April 24, 2017	Phase 3

NCT01985893	Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V. OnkoDataMed GmbH	Metastatic Breast Cancer	2013/9/1	Phase 2
NCT03811418	iOMEDICO AG Arbeitsgemeinschaft für Internistische Onkologie Amgen	Advanced Breast Cancer HER2-positive Breast Cancer	2019/1/1	Phase 3
NCT02131064	Hoffmann-La Roche	Breast Neoplasms	2014/6/25	Phase 3
NCT00535509	King Faisal Specialist Hospital & Research Center	Breast Cancer	2007/6/1	Not Applicable
NCT01084876	Celltrion	Metastatic Breast Cancer	2010/6/1	Phase 3
NCT01185509	Dana-Farber Cancer Institute Brigham and Women's Hospital Beth Israel Deaconess Medical Center Massachusetts General Hospital Genentech, Inc.	Breast Cancer Metastatic Breast Cancer	2010/11/1	Phase 2
NCT01901146	Amgen Actavis Inc.	Breast Cancer	April 29, 2013	Phase 3
NCT00629499	SCRI Development Innovations, LLC Celgene Corporation	Breast Cancer	April 2008	Phase 2
NCT02229149	US Oncology Research Genentech, Inc.	Breast Neoplasms Malignant Tumor of the Breast	2014/12/1	Phase 2
NCT02004769	Sun Yat-sen University Fudan University 307 Hospital of PLA Shandong Tumor Hospital Tongji Hospital West China Hospital Shandong Provincial Hospital Second Affiliated Hospital of Suzhou University Tianjin Medical University General Hospital Second Affiliated Hospital, School of Medicine, Zhejiang University Sixth Affiliated Hospital, Sun Yat-sen University Nanfang Hospital of Southern Medical University	Stomach Neoplasms Neoplasms Metastasis ERBB2 Gene Amplification	2013/11/1	Phase 2
NCT02006667	Hoffmann-La Roche	Urinary Tract Cancer	2001/1/1	Phase 2
NCT03767335	Menarini Group	Advanced or Metastatic Breast Cancer	2018/7/19	Phase 1
NCT01975142	Institut Curie	Metastatic Breast Cancer, HER2 Negative Primary Tumor	2013/11/7	Phase 2
NCT03950271	Henan Cancer Hospital	Gastric Cancer	2020/1/21	Phase 2
NCT01423695	WiSP Wissenschaftlicher Service Pharma GmbH Bristol-Myers Squibb Roche Pharma AG	Metastatic Breast Cancer	2001/2/1	Phase 2
NCT02954536	Memorial Sloan Kettering Cancer Center	Esophageal Cancer Gastric Cancer	2016/11/3	Phase 2
NCT00542451	Eric P Winer, MD Brigham and Women's Hospital Beth Israel Deaconess Medical Center Massachusetts General Hospital Genentech, Inc. Dana-Farber Cancer Institute	Breast Cancer Carcinoma of the Breast	2007/10/1	Phase 2
NCT04236310	Ruijin Hospital Jiangsu HengRui Medicine Co., Ltd.	Breast Cancer HER2-positive Breast Cancer ER-positive Breast Cancer	2020/1/15	Phase 2

NCT00841828	Spanish Breast Cancer Research Group GlaxoSmithKline	Breast Cancer	2009/2/1	Phase 2
NCT01306942	Spanish Breast Cancer Research Group Bristol-Myers Squibb	Metastatic Breast Cancer	2011/7/1	Phase 1 Phase 2
NCT03571633	Centre Leon Berard Amgen	HER2-positive Breast Cancer Operable Breast Cancer	2018/8/6	Phase 2
NCT02536339	Genentech, Inc.	Metastatic Breast Cancer	2015/12/16	Phase 2
NCT04337658	Second Affiliated Hospital, School of Medicine, Zhejiang University	HER2-positive Breast Cancer	2020/7/1	Phase 3
NCT04893109	Dana-Farber Cancer Institute Genentech, Inc.	Breast Cancer HER2-positive Breast Cancer	2021/6/16	Phase 2
NCT02649686	Canadian Cancer Trials Group AstraZeneca	Metastatic Breast Cancer	April 21, 2016	Phase 1
NCT01921335	Dana-Farber Cancer Institute Array BioPharma Breast Cancer Research Foundation	Brain Metastases From HER2 and Breast Cancer Advanced HER2-positive Breast Cancer	2013/8/1	Phase 1
NCT03989037	Shanghai Institute Of Biological Products Fudan University	HER2-positive Early Breast Cancer	2019/6/30	Phase 3
NCT00943670	Genentech, Inc.	Metastatic Breast Cancer	2009/7/1	Phase 2
NCT00444587	Hoffmann-La Roche	Breast Cancer	2007/3/1	Phase 2
NCT00618657	University of California, Irvine National Institutes of Health (NIH) National Cancer Institute (NCI)	Breast Cancer HER2-negative Breast Cancer HER2-positive Breast Cancer Recurrent Breast Cancer Stage IA Breast Cancer Stage IB Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer	2008/2/1	Phase 2
NCT04579380	Seagen Inc.	Uterine Neoplasms Uterine Cervical Neoplasms Biliary Tract Neoplasms Urologic Neoplasms Carcinoma, Non-Small-Cell Lung Breast Neoplasms	2021/1/11	Phase 2
NCT03112590	H. Lee Moffitt Cancer Center and Research Institute Horizon Pharma Ireland, Ltd., Dublin Ireland	Breast Cancer Breast Cancer, Male Breast Cancer Female HER2-positive Breast Cancer	2017/6/23	Phase 1 Phase 2
NCT01423123	NSABP Foundation Inc Pfizer	Breast Cancer	2011/5/1	Phase 1
NCT03058939	University of Chicago	Breast Cancer Breast Cancer Stage II Breast Cancer Stage III	2018/11/1	Phase 2
NCT01275677	National Cancer Institute (NCI) NRG Oncology	HER2+Neu Positive Progesterone Receptor Positive Recurrent Breast Carcinoma Stage IA Breast Cancer AJCC v7 Stage IB Breast Cancer AJCC v7 Stage IIA Breast Cancer AJCC v6 and v7 Stage IIB Breast Cancer AJCC v6 and v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7	2011/1/6	Phase 3
NCT00301899	National Institutes of Health Clinical Center (CC) National Cancer Institute (NCI)	Breast Cancer	2005/12/1	Phase 2
NCT04102618	Oncolytics Biotech SOLTI Breast Cancer Research Group	Breast Cancer	2019/3/29	Early Phase 1

NCT03615326	Merck Sharp & Dohme Corp.	Gastric Neoplasms Gastroesophageal Junction Adenocarcinoma	2018/10/5	Phase 3
NCT04152057	West China Hospital Jiangsu HengRui Medicine Co., Ltd.	Breast Cancer HER2 Positive Combination Chemotherapy	2019/11/1	Phase 1 Phase 2
NCT03931551	MedSIR	Advanced Breast Cancer	April 30, 2019	Phase 2
NCT03523572	Daiichi Sankyo, Inc. Bristol-Myers Squibb AstraZeneca	Breast Cancer Urothelial Carcinoma	2018/6/20	Phase 1
NCT01891357	West German Study Group GlaxoSmithKline	Carcinoma, Ductal, Breast	2013/9/30	Phase 2
NCT00038402	M.D. Anderson Cancer Center Genentech, Inc.	Breast Cancer	April 2001	Phase 3
NCT02568839	Thomas Hatschek Karolinska University Hospital	Early-Stage Breast Carcinoma HER-2 Positive Breast Cancer	2014/11/1	Phase 2 Phase 3
NCT02827877	City of Hope Medical Center National Cancer Institute (NCI)	HER2 Positive Breast Carcinoma Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer	2016/7/15	Phase 2
NCT00127933	Hoffmann-La Roche	Breast Cancer	2005/8/1	Phase 4
NCT04588545	H. Lee Moffitt Cancer Center and Research Institute Genentech, Inc.	HER2-positive Breast Cancer Leptomeningeal Metastasis Leptomeningeal Disease	2020/12/10	Phase 1 Phase 2
NCT00726180	University of Michigan Rogel Cancer Center	Breast Cancer	2008/7/1	Phase 1 Phase 2
NCT02339532	UNICANCER	Breast Cancer	2015/1/1	Phase 2
NCT00130507	Spanish Breast Cancer Research Group Hoffmann-La Roche	Breast Cancer	2005/11/4	Phase 2
NCT02025192	Seagen Inc.	HER2 Positive Metastatic Breast Cancers	2013/12/31	Phase 1
NCT01387373	Dorte Nielsen Herlev Hospital	Metastatic Breast Cancer Liver Metastases	April 2010	Phase 2
NCT01702571	Hoffmann-La Roche	Breast Cancer	2012/11/27	Phase 3
NCT01779050	Washington University School of Medicine Genentech, Inc.	Breast Neoplasms	2013/12/19	Phase 2
NCT02675231	Eli Lilly and Company	Hormone Receptor Positive Breast Cancer HER-2 Positive Breast Cancer	2016/5/23	Phase 2
NCT02213042	Novartis Pharmaceuticals Novartis	Neoplasms, Breast	2014/10/24	Phase 2
NCT00548184	Baylor Breast Care Center GlaxoSmithKline	Breast Cancer	2008/5/1	Phase 2
NCT03144947	Gruppo Oncologico Italiano di Ricerca Clinica University Hospital of Parma: Department of Biomedical, Biotechnological and Translational Sciences, Pathological Anatomy and Histology Unit University Hospital of Parma: Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology University Hospital of Parma: Statistica medica ed epidemiologia clinica-UO Ricerca e Innovazione Clirest s.r.l. Mipharm SpA Arithmos srl Temas srl	Cancer, Breast	2016/11/29	Phase 2

NCT00429104	M.D. Anderson Cancer Center Bayer	Breast Cancer	2002/8/1	Phase 2
NCT02789657	William Sikov MD Women and Infants Hospital of Rhode Island Rhode Island Hospital The Miriam Hospital Brown University	Breast Cancer	2016/11/1	Phase 2
NCT04789096	Breast Cancer Trials, Australia and New Zealand	Breast Cancer HER2-positive Breast Cancer	2021/6/1	Phase 2
NCT00515411	Memorial Sloan Kettering Cancer Center Sanofi Roche-Genentech City of Hope National Medical Center Piedmont Hospital Research Institute Medical College of Wisconsin Queens Health Network Weill Medical College of Cornell University Memorial Cancer Institute, Florida University of Pittsburgh Long Island Jewish Medical Center Nebraska Cancer Specialists Methodist Estabrook Cancer Center	Gastroesophageal Junction Adenocarcinoma Gastric Cancer	2006/10/23	Phase 2
NCT00736970	Merck Sharp & Dohme Corp.	Breast Cancer Breast Neoplasms	2008/7/1	Phase 2
NCT03588533	Sung Yong Oh Celltrion Dong-A University Hospital	HER-2 Positive Gastric Cancer Metastatic Cancer	2018/6/10	Phase 2
NCT00605397	Memorial Sloan Kettering Cancer Center	Breast Cancer	2007/1/1	Phase 1
NCT02947685	Alliance Foundation Trials, LLC. Pfizer German Breast Group Fondazione Michelangelo PrECOG, LLC. Breast Cancer Trials, Australia and New Zealand Syneos Health SOLTI Breast Cancer Research Group UNICANCER	HER-2 Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	2017/6/21	Phase 3
NCT01187381	Hoffmann-La Roche	Breast Cancer	April 14, 2010	
NCT03738553	University of Washington	HER2-positive Breast Cancer	2013/8/1	
NCT04752059	Medical University of Vienna Daiichi Sankyo, Inc.	Breast Cancer Stage IV	2020/7/28	Phase 2
NCT04632992	Genentech, Inc.	Advanced Unresectable or Metastatic Solid Malignancy	2021/1/13	Phase 2
NCT03262935	Byondis B.V.	Metastatic Breast Cancer	2017/11/30	Phase 3
NCT04928261	Ottawa Hospital Research Institute	Breast Cancer	2021/8/1	Phase 4
NCT00943410	UNC Lineberger Comprehensive Cancer Center National Cancer Institute (NCI)	Breast Cancer	2000/3/1	Phase 2
NCT00949247	Case Comprehensive Cancer Center	Breast Cancer	2009/12/1	Early Phase 1
NCT00629278	Azienda Ospedaliero-Universitaria di Modena National Cancer Institute (NCI)	Breast Cancer	2007/12/1	Phase 3
NCT00193063	SCRI Development Innovations, LLC Eli Lilly and Company Genentech, Inc.	Breast Cancer	2001/7/1	Phase 2

NCT02682693	German Breast Group Amgen Celgene Corporation	Breast Cancer Female NOS Tubular Breast Cancer Stage II Mucinous Breast Cancer Stage II Invasive Ductal Breast Cancer HER2 Positive Breast Cancer Inflammatory Breast Cancer Tubular Breast Cancer Stage III	2017/2/13	Phase 2
NCT04341181	Ulrik Lassen Roche Pharma AG Pfizer GlaxoSmithKline Rigshospitalet, Denmark	Cancer Tumors Neoplasms Neoplasia	2020/8/24	Phase 2
NCT01295086	Odense University Hospital Aalborg University Hospital Aarhus University Hospital Rigshospitalet, Denmark	Adenocarcinoma	2011/3/1	Not Applicable
NCT04510285	Memorial Sloan Kettering Cancer Center	Esophagogastric Tumors Gastric Cancer Gastric Tumor Esophageal Cancer Esophageal Neoplasms Esophageal Tumor GastroEsophageal Cancer Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Tumor Gastroesophageal Junction Cancer	2020/8/10	Phase 2
NCT01603264	Pfizer	Healthy	2012/5/1	Phase 1
NCT01373710	Institut Curie Hoffmann-La Roche Centre Leon Berard Groupe Hospitalier Pitie-Salpetriere Centre Oscar Lambret Centre Francois Baclesse Institut Bergonié University Hospital, Toulouse Institut du Cancer de Montpellier - Val d'Aurelle University Hospital, Grenoble	Metastatic Breast Cancer Carcinomatous Meningitis	2011/5/19	Phase 1 Phase 2
NCT01471847	Novartis Pharmaceuticals Novartis	Locally Advance Breast Cancer (LABC) Metastatic Breast Cancer (MBC)	2012/2/1	Phase 1
NCT04739761	AstraZeneca Daiichi Sankyo, Inc.	Breast Cancer	2021/6/22	Phase 3
NCT05076695	Fudan University	Estrogen Receptor-positive Breast Cancer HER2-positive Breast Cancer	2021/10/15	Phase 2
NCT01358877	Hoffmann-La Roche Genentech, Inc. Breast International Group	Breast Cancer	2011/11/8	Phase 3
NCT04049409	Taizhou Mabtech Pharmaceutical Co.,Ltd	Healthy Volunteers	2019/6/17	Phase 1
NCT02073487	The Methodist Hospital Research Institute Celgene Corporation Novartis	Breast Cancer	2014/2/1	Phase 2
NCT01402401	Novartis Pharmaceuticals Novartis	Advanced Gastric Cancer	2011/11/1	Phase 2
NCT01839500	Hoffmann-La Roche	Gastric Cancer	April 25, 2013	
NCT00493649	US Oncology Research Sanofi	Breast Cancer	2007/6/1	Phase 2
NCT00006825	NYU Langone Health National Cancer Institute (NCI)	Breast Cancer	2000/7/1	Phase 1 Phase 2
NCT02149524	Samsung Bioepis Co., Ltd.	HER2 Positive Early or Locally Advanced Breast Cancer	April 2014	Phase 3

NCT04253561	SOLTI Breast Cancer Research Group Roche Pharma AG	Metastatic Breast Cancer	2020/2/25	Phase 1
NCT00687440	Merck Sharp & Dohme Corp. MDS Pharma Services	Breast Neoplasm	2005/7/15	Phase 2
NCT00148681	Dana-Farber Cancer Institute Massachusetts General Hospital Beth Israel Deaconess Medical Center Brigham and Women's Hospital	Breast Cancer Stage II Breast Cancer Stage III Breast Cancer	2001/5/1	Phase 2
NCT00864175	Incyte Corporation	Breast Cancer	2007/7/1	Phase 1 Phase 2
NCT01427244	Yale University Genentech, Inc.	Paget's Disease of the Vulva	2011/8/1	Phase 2
NCT00520975	National Cancer Institute (NCI)	Breast Carcinoma Recurrent Breast Carcinoma Stage IV Breast Cancer	2007/11/1	Phase 3
NCT03365882	Southwest Oncology Group National Cancer Institute (NCI)	Colon Adenocarcinoma ERBB2 Gene Amplification Rectal Adenocarcinoma Recurrent Colon Carcinoma Recurrent Rectal Carcinoma Stage III Colon Cancer AJCC v7 Stage III Rectal Cancer AJCC v7 Stage IIIA Colon Cancer AJCC v7 Stage IIIA Rectal Cancer AJCC v7 Stage IIIB Colon Cancer AJCC v7 Stage IIIB Rectal Cancer AJCC v7 Stage IIIC Colon Cancer AJCC v7 Stage IIIC Rectal Cancer AJCC v7 Stage IV Colon Cancer AJCC v7 Stage IV Rectal Cancer AJCC v7 Stage IVA Colon Cancer AJCC v7 Stage IVA Rectal Cancer AJCC v7 Stage IVB Colon Cancer AJCC v7 Stage IVB Rectal Cancer AJCC v7	2017/10/9	Phase 2
NCT02057133	Eli Lilly and Company	Breast Neoplasms	2014/3/10	Phase 1
NCT00054470	The University of Texas Health Science Center at San Antonio National Cancer Institute (NCI)	Breast Cancer	2002/12/1	Phase 2
NCT00524303	GlaxoSmithKline	Neoplasms, Breast	2007/8/1	Phase 2
NCT02318901	Western Regional Medical Center	Advanced Cancer Breast Cancer Gastric Cancer Esophageal Cancer Colorectal Cancer	2014/10/1	Phase 1 Phase 2
NCT03498521	Hoffmann-La Roche Foundation Medicine, Inc.	Cancer of Unknown Primary Site	2018/7/10	Phase 2
NCT04395508	Genentech, Inc.	HER2-positive Breast Cancer		
NCT04379596	AstraZeneca Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo	Gastric Cancer	2020/6/3	Phase 2
NCT00770809	National Cancer Institute (NCI)	Male Breast Carcinoma Stage IIA Breast Cancer AJCC v6 and v7 Stage IIB Breast Cancer AJCC v6 and v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7	2008/12/1	Phase 3
NCT04616560	National Cancer Institute (NCI)	Osteosarcoma Recurrent Osteosarcoma	2021/2/1	Phase 2
NCT03613168	Changhoon Yoo Asan Medical Center	Cholangiocarcinoma Biliary Tract Cancer HER-2 Protein Overexpression HER-2 Gene Amplification	2019/6/1	Phase 2

NCT00006108	UNC Lineberger Comprehensive Cancer Center National Cancer Institute (NCI)	Breast Cancer	1999/8/1	Phase 1 Phase 2
NCT00821886	SCRI Development Innovations, LLC Bristol-Myers Squibb Genentech, Inc.	Breast Cancer	2009/2/1	Phase 2
NCT04686305	AstraZeneca Daiichi Sankyo, Inc.	Locally Advanced or Metastatic Non-Small Cell Lung Cancer	2021/3/9	Phase 1
NCT01152606	Hoffmann-La Roche	Breast Cancer	2007/8/30	
NCT01973660	SOLTI Breast Cancer Research Group Novartis	Breast Cancer	2013/10/1	Phase 2
NCT03907800	Ruijin Hospital	Breast Cancer Triple Negative Breast Cancer HER2-positive Breast Cancer	April 1, 2019	Phase 2
NCT01142778	Hoffmann-La Roche	Breast Cancer	2010/5/19	Phase 2
NCT02205047	European Organisation for Research and Treatment of Cancer - EORTC	Malignant Neoplasm of Stomach Malignant Neoplasm of Cardio-esophageal Junction of Stomach Epidermal Growth Factor Receptor (EGFR) Protein Overexpression	2015/9/1	Phase 2
NCT00295893	City of Hope Medical Center National Cancer Institute (NCI)	Breast Cancer	2005/9/14	Phase 2
NCT01042379	QuantumLeap Healthcare Collaborative	Breast Neoplasms Breast Cancer Breast Tumors Angiosarcoma TNBC - Triple-Negative Breast Cancer HER2-positive Breast Cancer HER2-negative Breast Cancer Hormone Receptor Positive Tumor Hormone Receptor Negative Tumor Early-stage Breast Cancer Locally Advanced Breast Cancer	2010/3/1	Phase 2
NCT00490139	Novartis Pharmaceuticals North Central Cancer Treatment Group National Cancer Institute (NCI) Breast International Group Canadian Cancer Trials Group Novartis	Neoplasms, Breast	2007/5/16	Phase 3
NCT01875367	Spanish Breast Cancer Research Group	Breast Cancer	2013/9/18	Phase 3
NCT01796197	Dana-Farber Cancer Institute	Breast Cancer	2013/8/1	Phase 2
NCT00320385	GlaxoSmithKline	Neoplasms, Breast	2005/11/1	Phase 3
NCT00151034	University of Michigan Rogel Cancer Center Genentech, Inc.	Urologic Neoplasms	2000/9/1	Phase 2
NCT05020860	Baylor Breast Care Center	Breast Cancer Breast Neoplasm Breast Cancer Female Breast Cancer Invasive Breast Cancer Stage II Breast Cancer Stage III Triple Negative Breast Cancer Hormone Receptor-positive Breast Cancer HER2-positive Breast Cancer Triple Negative Breast Neoplasms Estrogen Receptor-positive Breast Cancer	2021/10/15	Phase 2
NCT00054587	UNICANCER	Breast Cancer	2001/6/1	Phase 3

NCT02252887	Memorial Sloan Kettering Cancer Center Genentech, Inc. Hoffmann-La Roche Hartford HealthCare	Metastatic HER2-Positive Breast Cancer	2015/1/12	Phase 2
NCT03726879	Hoffmann-La Roche Chugai Pharmaceutical	Breast Cancer	2019/1/11	Phase 3
NCT01191697	Dana-Farber Cancer Institute Brigham and Women's Hospital Massachusetts General Hospital Genentech, Inc.	Esophageal Cancer Gastric Cancer	2011/2/1	Phase 2
NCT00146549	Dana-Farber Cancer Institute Massachusetts General Hospital Brigham and Women's Hospital North Shore Medical Center GlaxoSmithKline	Breast Cancer Stage IV Breast Cancer	2001/8/1	Phase 3
NCT02678182	Royal Marsden NHS Foundation Trust MedImmune LLC Clovis Oncology, Inc. Eli Lilly and Company	Adenocarcinoma of the Oesophagus Adenocarcinoma of the Gastro-oesophageal Junction Adenocarcinoma of the Stomach	2015/2/1	Phase 2
NCT00238290	Swiss Group for Clinical Cancer Research	Breast Cancer	2005/5/1	Phase 2
NCT01363986	Hoffmann-La Roche	Breast Cancer	2011/9/1	Phase 2
NCT00033514	Jonsson Comprehensive Cancer Center Genentech, Inc.	Breast Cancer	2001/8/1	Phase 1 Phase 2
NCT01810393	Hoffmann-La Roche	Breast Cancer	2013/6/11	Phase 3
NCT01748773	Hoffmann-La Roche	Gastric Cancer Gastroesophageal Junction Cancer	2013/1/29	Phase 2
NCT04900311	Tianjin Medical University Cancer Institute and Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	HER2+; Early or Locally Advanced Breast Cancer	2021/5/1	Phase 2
NCT00191373	Eli Lilly and Company	Breast Neoplasms Cancer of the Breast Breast Cancer	2002/3/1	Phase 2
NCT02658461	Hoffmann-La Roche	Breast Cancer	2012/2/1	
NCT00022672	Hoffmann-La Roche Genentech, Inc.	Breast Cancer	2001/1/1	Phase 3
NCT00593697	Finnish Breast Cancer Group	Breast Neoplasms	2008/1/1	Phase 3
NCT01125566	Boehringer Ingelheim	Breast Neoplasms	2010/6/22	Phase 3
NCT04494425	AstraZeneca Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo	Advanced or Metastatic Breast Cancer	2020/7/24	Phase 3
NCT02725541	Jenny C. Chang, MD Genentech, Inc. The Methodist Hospital Research Institute	Breast Cancer	2016/3/1	Phase 2
NCT03588091	Jiangsu HengRui Medicine Co., Ltd.	HER2-positive Breast Cancer	2018/7/24	Phase 3
NCT03783936	Autumn McRee, MD EMD Serono University of North Carolina, Chapel Hill Hoosier Cancer Research Network	Gastric Adenocarcinoma Esophageal Adenocarcinoma Metastasis HER-2 Gene Amplification	2019/1/24	Phase 2
NCT04262804	Zai Lab (Shanghai) Co., Ltd. Zai Lab (Hong Kong), Ltd.	Breast Cancer Metastatic	2020/1/13	Phase 2
NCT00006110	UNC Lineberger Comprehensive Cancer Center	Breast Cancer	1998/12/1	Phase 2

NCT00024154	National Cancer Institute (NCI)	Male Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer	2002/2/1	Phase 2
NCT00077376	National Cancer Institute (NCI)	HER2-positive Breast Cancer Male Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer	2005/3/1	Phase 2
NCT04591431	Fondazione per la Medicina Personalizzata	Breast Cancer Gastrointestinal Cancer Non Small Cell Lung Cancer Other Cancer	2020/10/7	Phase 2
NCT02100917	Meiji Seika Pharma Co., Ltd. Dong-A Pharmaceutical	Healthy Volunteer	2014/1/1	Phase 1
NCT02581748	Shanghai Henlius Biotech	Healthy	2015/9/16	Phase 1
NCT01959386	Hoffmann-La Roche	Breast Neoplasms	2013/11/7	
NCT02472964	Mylan Inc. Mylan GmbH	Breast Cancer	2012/7/1	Phase 3
NCT01772472	Hoffmann-La Roche NSABP Foundation Inc German Breast Group	Breast Cancer	April 3, 2013	Phase 3
NCT01104571	Institute of Cancer Research, United Kingdom University of Manchester Manchester University NHS Foundation Trust Cancer Research UK Novartis	Breast Cancer	April 2010	Phase 3
NCT00637325	Regione Lombardia Mario Negri Institute for Pharmacological Research Istituto Clinico Humanitas	Metastatic or Locally Advanced Breast Cancer	2007/11/1	Phase 3
NCT01774786	Hoffmann-La Roche	Gastric Cancer	2013/6/10	Phase 3
NCT02091141	Genentech, Inc.	Neoplasms Solid Tumors Biliary Cancer Salivary Cancer Bladder Cancer	April 14, 2014	Phase 2
NCT03698383	Korean Cancer Study Group	HER2-positive Breast Cancer Metastatic Breast Cancer	2019/12/3	Phase 2
NCT00674414	UNICANCER	Breast Cancer	April 2008	Phase 2
NCT00482391	Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) Dana-Farber Cancer Institute GlaxoSmithKline	Breast Cancer	2007/3/1	Phase 2
NCT01572038	Hoffmann-La Roche	Breast Neoplasms	2012/6/1	Phase 3
NCT03379428	US Oncology Research AbbVie Pharmacyclics LLC.	Breast Neoplasms Malignant Neoplasm of Breast	2017/11/29	Phase 1 Phase 2
NCT00258960	Spanish Breast Cancer Research Group Schering-Plough	Breast Cancer	2006/2/15	Phase 2
NCT01566721	Hoffmann-La Roche	Breast Neoplasms	2012/5/17	Phase 3
NCT04367090	Jiangsu HengRui Medicine Co., Ltd.	Metastatic Breast Cancer	April 2020	Phase 1
NCT04034823	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	HER2-positive Breast Cancer	2019/9/1	Phase 2
NCT01785420	Dr Rajendra A. Badwe Tata Memorial Hospital	Carcinoma Breast Stage I HER2 Positive Breast Cancer	2013/5/1	Phase 3

NCT03501979	University of Alabama at Birmingham Translational Breast Cancer Research Consortium Johns Hopkins University Seagen Inc. University of Michigan Georgetown University University of California, San Francisco University of Chicago Indiana University University of Washington University of Texas	Metastatic Breast Cancer Leptomeningeal Disease	2019/2/20	Phase 2
NCT00795678	Case Comprehensive Cancer Center United States Department of Defense National Cancer Institute (NCI)	Breast Cancer Metastatic Cancer	2008/9/1	
NCT02530424	Fondazione Michelangelo	Breast Neoplasms	2015/5/1	Phase 2
NCT00486668	NSABP Foundation Inc GlaxoSmithKline	Invasive Breast Cancer	2007/7/1	Phase 3
NCT04717531	The First Affiliated Hospital with Nanjing Medical University	Breast Cancer	2021/6/3	Phase 2
NCT04296162	Fudan University	Breast Cancer	2019/3/1	Phase 2
NCT02125344	German Breast Group Amgen Roche Pharma AG Teva Pharmaceuticals USA Vifor Pharma	Tubular Breast Cancer Stage II Tubular Breast Cancer Stage III Mucinous Breast Cancer Stage II Breast Cancer Female NOS Invasive Ductal Breast Cancer HER2 Positive Breast Cancer Inflammatory Breast Cancer	2014/12/1	Phase 3
NCT00182793	City of Hope Medical Center National Cancer Institute (NCI)	Breast Cancer	2005/7/1	Phase 2
NCT03179904	Mayo Clinic National Cancer Institute (NCI)	Advanced Breast Carcinoma HER2 Positive Breast Carcinoma Stage III Breast Cancer AJCC v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7	2017/9/25	Phase 2
NCT03742986	NYU Langone Health	Breast Cancer	2019/5/2	Phase 2
NCT00781612	Genentech, Inc. Hoffmann-La Roche	Neoplasm Metastasis	2008/10/16	Phase 2
NCT00470704	Nancy Lin, MD GlaxoSmithKline Novartis Dana-Farber Cancer Institute	Breast Cancer	2007/5/14	Phase 2
NCT01926886	Hoffmann-La Roche	Breast Cancer	2013/11/19	Phase 3
NCT02593708	Michelle Melisko University of California, San Francisco	Solid Tumor	2015/11/3	Phase 1
NCT01853748	Dana-Farber Cancer Institute	Breast Cancer	2013/5/1	Phase 2
NCT03766607	Korean South West Oncology Group	Gastric Cancer	2019/9/30	Phase 2
NCT02836847	Shanghai Jiao Tong University School of Medicine Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Ruijin Hospital RenJi Hospital Eastern Hepatobiliary Surgery Hospital Huashan Hospital	Cholangiocarcinoma of the Extrahepatic Bile Duct Gallbladder Cancer	2016/7/1	Phase 2

NCT04088110	Fuzhou General Hospital	Breast Cancer Female HER2-positive Breast Cancer Hormone Receptor Positive Malignant Neoplasm of Breast Metastatic Breast Cancer Breast Diseases Hormone Receptor Positive Tumor	2019/11/1	Phase 2
NCT00567879	Novartis Pharmaceuticals Novartis	Breast Cancer	April 2008	Phase 1 Phase 2
NCT04158856	xuexin he Second Affiliated Hospital, School of Medicine, Zhejiang University	HER2-positive Breast Cancer	2020/6/1	Phase 2
NCT00006381	Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI)	Breast Cancer	2000/6/1	Phase 2
NCT00107393	Tohoku University National Cancer Institute (NCI)	Breast Cancer	2003/6/1	Phase 2
NCT02154529	Kadmon Corporation, LLC	HER-2 Positive Breast Cancer Metastatic Malignant Neoplasm to Brain	2014/5/1	Phase 1 Phase 2
NCT04639271	Shandong Cancer Hospital and Institute	Breast Cancer HER2-positive Breast Cancer	2021/1/1	Phase 2
NCT00712140	Warwick Medical School National Cancer Institute (NCI)	Breast Cancer	2007/10/1	Phase 3
NCT00365365	Sanofi	Breast Cancer	2006/8/1	Phase 2
NCT01160211	Novartis Pharmaceuticals GlaxoSmithKline Novartis	Neoplasms, Breast	2011/5/5	Phase 3
NCT01004172	Dana-Farber Cancer Institute Brigham and Women's Hospital Massachusetts General Hospital Beth Israel Deaconess Medical Center Genentech, Inc.	Metastatic Breast Cancer Breast Cancer Progressive Breast Cancer	2009/11/1	Phase 2
NCT01008150	NSABP Foundation Inc Puma Biotechnology, Inc.	Breast Cancer	2010/10/1	Phase 2
NCT00717405	Hoffmann-La Roche	Breast Cancer	2008/10/1	Phase 2
NCT00301730	National Cancer Institute (NCI)	Breast Cancer Metastatic Cancer	2005/10/1	Phase 1
NCT02213289	University of Chicago AbbVie	Adenocarcinoma	2015/1/20	Phase 2
NCT02705859	Cancer Trials Ireland	HER2 Positive Breast Cancer	April 2016	Phase 1
NCT01855828	Yale University Genentech, Inc.	Her2-Positive Breast Cancer	2013/9/1	Phase 2

NCT04329065	University of Washington National Cancer Institute (NCI) United States Department of Defense	Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8	2021/11/1	Phase 2
NCT00136539	Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Genentech, Inc. Bristol-Myers Squibb Massachusetts General Hospital Beth Israel Deaconess Medical Center Harvard Vanguard Medical Associates Brigham and Women's Hospital	Breast Cancer	1999/3/1	Phase 2
NCT00005857	City of Hope Medical Center National Cancer Institute (NCI)	Prostate Cancer	2000/8/1	Phase 2
NCT04298918	Hoffmann-La Roche	Breast Cancer	2020/9/23	Phase 1 Phase 2
NCT00003539	Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI)	Breast Cancer	April 1998	Phase 2

NCT02465060	National Cancer Institute (NCI)	Advanced Malignant Solid Neoplasm Bladder Carcinoma Breast Carcinoma Cervical Carcinoma Colon Carcinoma Colorectal Carcinoma Endometrial Carcinoma Esophageal Carcinoma Gastric Carcinoma Glioma Head and Neck Carcinoma Kidney Carcinoma Liver and Intrahepatic Bile Duct Carcinoma Lung Carcinoma Lymphoma Malignant Uterine Neoplasm Melanoma Ovarian Carcinoma Pancreatic Carcinoma Plasma Cell Myeloma Prostate Carcinoma Rectal Carcinoma Recurrent Bladder Carcinoma Recurrent Breast Carcinoma Recurrent Cervical Carcinoma Recurrent Colon Carcinoma Recurrent Colorectal Carcinoma Recurrent Esophageal Carcinoma Recurrent Gastric Carcinoma Recurrent Glioma Recurrent Head and Neck Carcinoma Recurrent Liver Carcinoma Recurrent Lung Carcinoma Recurrent Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Melanoma Recurrent Ovarian Carcinoma Recurrent Pancreatic Carcinoma Recurrent Plasma Cell Myeloma Recurrent Prostate Carcinoma Recurrent Rectal Carcinoma Recurrent Skin Carcinoma Recurrent Thyroid Gland Carcinoma Recurrent Uterine Corpus Cancer Refractory Lymphoma Refractory Malignant Solid Neoplasm Refractory Plasma Cell Myeloma Skin Carcinoma Thyroid Gland Carcinoma Uterine Corpus Cancer	2015/8/12	Phase 2
NCT04784715	AstraZeneca Daiichi Sankyo, Inc.	Breast Cancer; HER2-positive; Metastatic	April 26, 2021	Phase 3
NCT04481932	Peking University	HER2-positive Breast Cancer	2020/7/1	Phase 2
NCT02725424	Chinese Academy of Medical Sciences	Gastric Cancer	2015/8/1	Phase 2
NCT03014076	Cancer Insight, LLC	Breastcancer	2008/1/1	Phase 1
NCT01260194	Hoffmann-La Roche	Gastric Cancer	2011/6/1	Phase 4
NCT01205217	GlaxoSmithKline	Neoplasms, Breast	2010/12/1	Phase 2
NCT00003992	National Cancer Institute (NCI)	Breast Cancer	1999/8/1	Phase 2
NCT04873362	Hoffmann-La Roche	Breast Cancer	2021/5/4	Phase 3
NCT02194166	Hoffmann-La Roche	Breast Cancer	2014/7/18	Phase 3
NCT00833963	Genentech, Inc.	Breast Cancer Pregnancy	2009/1/14	
NCT02005484	Hoffmann-La Roche	Gastric Cancer	2004/1/1	Phase 2
NCT03523585	Daiichi Sankyo, Inc. Daiichi Sankyo Co., Ltd. AstraZeneca	Breast Cancer	2018/8/1	Phase 3

NCT00006123	Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute	Breast Cancer	2000/7/1	Phase 1 Phase 2
NCT01928290	Washington University School of Medicine	Stomach Neoplasms Esophageal Neoplasms	2013/11/8	Phase 2
NCT02003209	National Cancer Institute (NCI) NRG Oncology	HER2-Positive Breast Carcinoma Hormone Receptor-Positive Breast Carcinoma Stage IB Breast Cancer AJCC v7 Stage IIA Breast Cancer AJCC v6 and v7 Stage IIB Breast Cancer AJCC v6 and v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7	2014/1/15	Phase 3
NCT01130337	Hoffmann-La Roche	Gastric Cancer	2010/7/1	Phase 2
NCT01491737	Hoffmann-La Roche	Breast Cancer	2012/2/17	Phase 2
NCT00003995	National Cancer Institute (NCI)	Colorectal Cancer	1999/9/1	Phase 2
NCT02380131	Hebei Medical University	HER-2 Positive Gastric Cancer Liver Metastasis	2013/2/1	Phase 4
NCT00820872	Alliance for Clinical Trials in Oncology National Cancer Institute (NCI)	Breast Cancer	2009/2/1	Phase 2
NCT02514681	Japan Breast Cancer Research Group Chugai Pharmaceutical	HER2-positive Locally Advanced or Metastatic Breast Cancer	2015/8/1	Phase 3
NCT03095352	Hope Rugo, MD Mayo Clinic Johns Hopkins University Translational Breast Cancer Research Consortium Massachusetts General Hospital Merck Sharp & Dohme Corp. University of California, San Francisco	Breast Cancer Chest Wall Disease	2017/9/2	Phase 2
NCT00401427	National Cancer Institute, Naples	Metastatic Breast Cancer	2002/11/1	Phase 2
NCT00057993	Northwestern University National Cancer Institute (NCI)	Breast Cancer	2002/7/1	Phase 2
NCT00811135	Hoffmann-La Roche	Breast Cancer	2008/12/1	Phase 2
NCT04380012	Second Affiliated Hospital, School of Medicine, Zhejiang University Zhejiang Cancer Hospital Zhejiang Provincial People's Hospital First Affiliated Hospital of Zhejiang University Sir Run Run Shaw Hospital	Colorectal Cancer	2019/12/17	Phase 2
NCT01597414	European Organisation for Research and Treatment of Cancer - EORTC Hoffmann-La Roche	Elderly Metastatic Breast Cancer Population	2013/6/1	Phase 2
NCT00800436	Hoffmann-La Roche	Breast Cancer	2008/11/1	Phase 1
NCT02665637	Celltrion	Healthy Volunteers	2015/12/1	Phase 1
NCT00639366	Anglo Celtic Cooperative Oncology Group National Cancer Institute (NCI)	Breast Cancer	2007/2/1	Phase 3
NCT05002127	ALX Oncology Inc. Eli Lilly and Company	Gastric Cancer Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma	2021/8/1	Phase 2 Phase 3

NCT00045032	Hoffmann-La Roche Breast International Group European Organisation for Research and Treatment of Cancer - EORTC NCIC Clinical Trials Group International Breast Cancer Study Group	Breast Cancer	2001/11/1	Phase 3
NCT01964391	Hoffmann-La Roche	Breast Cancer	2014/2/21	Phase 3
NCT01340430	Lucia Del Mastro,MD IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy	HER-2 Positive Breast Cancer	2011/3/1	Phase 2
NCT00951665	Genentech, Inc.	Metastatic Breast Cancer	2009/8/1	Phase 1 Phase 2
NCT02226276	City of Hope Medical Center National Cancer Institute (NCI)	Bone Metastases HER2-positive Breast Cancer Liver Metastases Lung Metastases Recurrent Breast Cancer Soft Tissue Metastases Stage IV Breast Cancer	2015/1/7	Not Applicable
NCT02102438	Instituto do Cancer do Estado de São Paulo	Breast Cancer HER-2 Positive Breast Cancer	April 2014	Not Applicable
NCT03368729	University of Alabama at Birmingham Translational Breast Cancer Research Consortium Tesaro, Inc. Susan G. Komen Breast Cancer Foundation Breast Cancer Research Foundation of Alabama VFoundation	Metastatic Breast Cancer HER2 Positive Breast Carcinoma	2019/9/6	Phase 1 Phase 2
NCT03556358	Tanvex BioPharma USA, Inc.	Breast Cancer Breast Neoplasms HER2-positive Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer	2018/6/28	Phase 3
NCT02492711	MacroGenics	HER-2 Positive Breast Cancer Metastatic Neoplasm	2015/8/24	Phase 3
NCT00251433	Novartis Pharmaceuticals Novartis	Neoplasms, Breast	2005/9/26	Phase 1
NCT00194779	University of Washington National Cancer Institute (NCI)	Estrogen Receptor-negative Breast Cancer Estrogen Receptor-positive Breast Cancer HER2-positive Breast Cancer Progesterone Receptor-negative Breast Cancer Progesterone Receptor-positive Breast Cancer Stage IA Breast Cancer Stage IB Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer	2003/10/1	Phase 2
NCT00201760	Kari Kendra Eli Lilly and Company Ohio State University Comprehensive Cancer Center	Breast Cancer	2005/2/25	Phase 2
NCT01472029	AIO-Studien-gGmbH Roche Pharma AG	Adenocarcinoma of the Gastroesophageal Junction Adenocarcinoma of the Stomach	2011/12/1	Phase 2
NCT01305941	UNC Lineberger Comprehensive Cancer Center Novartis Pharmaceuticals	HER-2 Positive Breast Cancer	2011/9/1	Phase 2

NCT01434303	National Cancer Institute (NCI)	HER2+Neu Positive Invasive Breast Carcinoma Recurrent Breast Carcinoma Stage IV Breast Cancer AJCC v6 and v7	2012/1/10	Phase 1
NCT04721977	Merck Sharp & Dohme Corp.	Breast Cancer	April 8, 2021	Phase 2
NCT01304797	Merrimack Pharmaceuticals	Breast Cancer	2011/3/1	Phase 1
NCT00364611	Sanofi	Breast Cancer	2006/8/1	Phase 2
NCT00016367	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Lung Cancer	1999/5/13	Phase 2
NCT01745965	West German Study Group Roche Pharma AG	Breast Cancer	2012/11/1	Phase 2
NCT00193089	SCRI Development Innovations, LLC Aventis Pharmaceuticals GlaxoSmithKline	Breast Cancer	April 2001	Phase 2
NCT00297596	SCRI Development Innovations, LLC Sanofi	Breast Cancer	2006/2/1	Phase 2
NCT02419742	Hoffmann-La Roche	Breast Cancer	2015/8/18	Phase 4
NCT01220128	GlaxoSmithKline	Neoplasms, Breast	April 11, 2011	Phase 2
NCT03013504	Prestige Biopharma Ltd	HER2 Positive Breast Cancer	2018/1/1	Phase 3
NCT02909751	Vejle Hospital	Breast Cancer	2016/9/14	Phase 2
NCT00303992	University of California, San Francisco National Cancer Institute (NCI)	Breast Cancer	2004/5/1	Phase 2
NCT00014430	Dartmouth-Hitchcock Medical Center National Cancer Institute (NCI)	Breast Cancer	1999/11/1	Phase 1
NCT01304784	Merrimack Pharmaceuticals	HER-2 Gene Amplification	2011/1/1	Phase 1
NCT04042051	Cancer Trials Ireland	HER2-positive Breast Cancer Metastatic Breast Cancer Locally Advanced Breast Cancer Unresectable Breast Cancer	2019/11/12	Phase 1
NCT00478140	National Cancer Institute (NCI)	Adenocarcinoma of the Extrahepatic Bile Duct Adenocarcinoma of the Gallbladder Malignant Neoplasm Recurrent Extrahepatic Bile Duct Cancer Recurrent Gallbladder Cancer Unresectable Extrahepatic Bile Duct Cancer Unresectable Gallbladder Cancer	2007/5/1	Phase 2
NCT01850628	NSABP Foundation Inc Breast Cancer Research Foundation Washington University School of Medicine	Breast Cancer	2013/7/1	
NCT03894007	Renske Altena Karolinska University Hospital	Early-stage Breast Cancer HER2-positive Breast Cancer	2019/5/23	Phase 2
NCT03264547	Japan Breast Cancer Research Group Eisai Co., Ltd.	Breast Cancer	2017/8/28	Phase 3
NCT02297698	Cancer Insight, LLC Genentech, Inc. Sellas Life Sciences Group	Breast Cancer	2014/10/1	Phase 2

NCT02774421	University of Colorado, Denver Children's Hospital Colorado	Posterior Fossa Ependymoma (PFEPN)	2016/12/1	Phase 1
NCT04888663	Yonsei University	Recurrent+Metastatic Gastric Cancer	2018/2/13	Phase 1 Phase 2
NCT01750073	University of Nebraska National Cancer Institute (NCI)	Estrogen Receptor Negative Estrogen Receptor Positive HER2+Neu Negative HER2+Neu Positive Invasive Breast Carcinoma Progesterone Receptor Negative Progesterone Receptor Positive Stage IA Breast Cancer Stage II Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer Stage III Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Triple-Negative Breast Carcinoma	2012/12/1	Phase 2
NCT00724360	Nantes University Hospital	Relapsed+Refractory Leukemia	2006/11/1	Phase 2
NCT02488564	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori	HER-2 Positive Breast Cancer	2014/12/17	Phase 2
NCT02693535	American Society of Clinical Oncology AstraZeneca Bayer Bristol-Myers Squibb Eli Lilly and Company Genentech, Inc. Merck Sharp & Dohme Corp. Pfizer Boehringer Ingelheim Seagen Inc.	Lymphoma, Non-Hodgkin Multiple Myeloma Advanced Solid Tumors	2016/3/14	Phase 2
NCT00407888	University of Washington National Cancer Institute (NCI)	Estrogen Receptor-positive Breast Cancer HER2-positive Breast Cancer Stage IA Breast Cancer Stage IB Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer	2006/5/1	Phase 2
NCT00331552	University of Washington National Cancer Institute (NCI)	HER2-positive Breast Cancer Male Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer	2006/2/1	Phase 1 Phase 2
NCT01401166	Hoffmann-La Roche	Breast Neoplasms	2011/10/1	Phase 2
NCT01847001	Columbia University	Locally Advanced Malignant Neoplasm Breast Cancer	2012/10/1	Phase 2
NCT00446030	Sanofi	Breast Neoplasms	2007/3/1	Phase 2
NCT00367471	Novartis Pharmaceuticals Novartis	Neoplasms, Breast	2006/12/7	Phase 1
NCT04539938	Seagen Inc.	Breast Cancer	2020/12/1	Phase 2
NCT00574587	Albert Einstein College of Medicine Merck Sharp & Dohme Corp.	Breast Cancer	2007/12/1	Phase 1 Phase 2
NCT04398914	Shanghai Jiao Tong University School of Medicine Jiangsu HengRui Medicine Co., Ltd.	Breast Cancer Invasive	2020/5/30	Phase 2
NCT01959490	Case Comprehensive Cancer Center National Cancer Institute (NCI)	Stage II Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer	2013/9/24	Phase 2

NCT00041067	Southwest Oncology Group National Cancer Institute (NCI)	Breast Cancer	2002/9/1	Phase 2
NCT01450696	Hoffmann-La Roche	Gastric Cancer	2011/12/1	Phase 3
NCT01480583	Angiochem Inc	Breast Cancer Brain Metastases	2011/10/1	Phase 2
NCT03414658	Ian E. Krop, MD, PhD Pfizer Breast Cancer Research Foundation Johns Hopkins University Dana-Farber Cancer Institute	Breast Cancer	2018/6/21	Phase 2
NCT00254592	University of California, Irvine	Breast Cancer	2005/10/1	Phase 2
NCT00272987	Novartis Pharmaceuticals Novartis	Neoplasms, Breast	2005/12/13	Phase 3
NCT00788931	Novartis Pharmaceuticals Novartis	HER-2 Positive Breast Cancer Metastatic Breast Cancer	2008/12/1	Phase 1
NCT00426556	Novartis Pharmaceuticals Novartis	Metastatic Breast Cancer	2007/7/1	Phase 1
NCT04301375	David Garcia Cinca Fundacion Clinic per a la Recerca Biomédica Hospital Clinic of Barcelona	Mammary Cancer	2020/6/15	Phase 2
NCT02320435	Hoffmann-La Roche	Solid Tumor	2015/2/2	Phase 3
NCT03239015	Baodong Qin Shanghai Changzheng Hospital	Rare Tumor Refractory Tumor	2017/1/1	Phase 2
NCT00392392	SCRI Development Innovations, LLC Celgene Corporation Genentech, Inc.	Breast Cancer	2006/10/1	Phase 2
NCT00148668	Eric Winer, MD Dana-Farber Cancer Institute Brigham and Women's Hospital Massachusetts General Hospital Beth Israel Deaconess Medical Center Yale University	Breast Cancer	2003/12/1	Phase 2
NCT00954512	Merck Sharp & Dohme Corp.	Neoplasms	2009/9/25	Phase 1 Phase 2
NCT03006172	Genentech, Inc.	Breast Cancer Solid Tumor	2016/12/13	Phase 1
NCT01007942	Novartis Pharmaceuticals Novartis	HER2+Neu Over-expressing Locally Advanced Breast Cancer Metastatic Breast Cancer	2009/10/1	Phase 3
NCT01480674	Hoffmann-La Roche	Breast Cancer	2011/3/28	
NCT00138125	Translational Oncology Research International University of California, Los Angeles Genentech, Inc. AstraZeneca	Breast Cancer	April 2005	Phase 2
NCT03185988	Shen Lin Peking University	Targeted Therapy HER2 Biliary Tract Cancer Esophageal Squamous Cell Carcinoma Colorectal Cancer	2017/7/1	Phase 2
NCT00134680	Duke University Genentech, Inc. Novartis Pharmaceuticals	Metastatic Breast Cancer	2000/1/1	Phase 2
NCT00553358	Novartis Pharmaceuticals Breast International Group SOLTI Breast Cancer Research Group Novartis	Neoplasms, Breast	2008/1/5	Phase 3
NCT02843126	Fuda Cancer Hospital, Guangzhou Shenzhen Hank Bioengineering Institute	Recurrent Breast Cancer	2016/7/1	Phase 1 Phase 2

NCT00036868	European Organisation for Research and Treatment of Cancer - EORTC	Breast Cancer	2002/2/1	Phase 2
NCT02059876	Guangdong Provincial People's Hospital	Breast Cancer	2013/11/1	Phase 2
NCT00824733	Bhuvaneswari Ramaswamy Pfizer Ohio State University Comprehensive Cancer Center	Breast Cancer	2009/2/1	Phase 2
NCT04680442	Population Health Research Institute	Breast Cancer Heart Failure	2021/5/1	Phase 2
NCT01461057	Hoffmann-La Roche	Gastric Cancer	2011/12/6	Phase 2
NCT04170595	Genor Biopharma Co., Ltd.	HER2-positive Breast Cancer	2014/3/28	Phase 1 Phase 2
NCT03432741	Mayo Clinic National Cancer Institute (NCI)	Breast Adenocarcinoma Metastatic Breast Carcinoma Recurrent Breast Carcinoma Recurrent Hodgkin Lymphoma Recurrent Mycosis Fungoides Recurrent Non-Hodgkin Lymphoma Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Refractory Breast Carcinoma Refractory Hodgkin Lymphoma Refractory Mycosis Fungoides Refractory Nodal Marginal Zone Lymphoma Refractory Non-Hodgkin Lymphoma Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Stage IV Breast Cancer AJCC v6 and v7	2018/3/27	Phase 1
NCT02000882	US Oncology Research Novartis Pharmaceuticals	Brain Metastases Breast Cancer Metastatic Breast Cancer	2014/5/29	Phase 2
NCT03367676	Ruijin Hospital	Breast Cancer	2017/12/30	Phase 2
NCT00679211	Genentech, Inc.	Metastatic Breast Cancer	2008/8/1	Phase 2
NCT00021255	Sanofi Cancer International Research Group (CIRG)	Breast Neoplasms	April 2001	Phase 3
NCT00847366	AEterna Zentaris	Non Small Cell Lung Cancer Solid Tumors Metastatic Breast Cancer Sarcomas	2008/5/1	Not Applicable
NCT00923299	Institut du Cancer de Montpellier - Val d'Aurelle	Pancreatic Cancer	2008/12/1	Phase 1 Phase 2
NCT02726399	Memorial Sloan Kettering Cancer Center	Gastric Cancer Gastroesophageal Junction Cancer	2016/3/18	Phase 2
NCT04886531	Ruth O'Regan Puma Biotechnology, Inc. University of Rochester Hoosier Cancer Research Network	Breast Cancer HER2-positive Breast Cancer ER Positive Breast Cancer PR-Positive Breast Cancer	2021/6/1	Phase 2
NCT00475670	Hoffmann-La Roche	Breast Cancer	2005/10/1	Phase 2
NCT02120911	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Roche Pharma AG	Esophageal Carcinoma	2014/1/1	Phase 1 Phase 2
NCT03784599	The Netherlands Cancer Institute AstraZeneca Roche Pharma AG	Carcinoma, Non-Small-Cell Lung	2018/12/18	Phase 2
NCT04960943	Fudan University	Gastrointestinal Tumor Effect of Drug	2020/2/1	Phase 2

NCT00490646	R-Pharm	Metastatic Breast Cancer	2008/2/1	Phase 2
NCT04644237	Daiichi Sankyo, Inc. AstraZeneca	Non-Small Cell Lung Cancer	2021/3/19	Phase 2
NCT01512199	Daiichi Sankyo, Inc.	Metastatic Breast Cancer	2011/11/1	Phase 1 Phase 2
NCT00317720	M.D. Anderson Cancer Center Novartis	Breast Cancer Neoplasm Metastasis	April 2006	Phase 1 Phase 2
NCT05020964	Chinese Academy of Medical Sciences	Advanced Breast Cancer	2021/8/20	Phase 2
NCT00171847	Novartis Pharmaceuticals Roche - Prof. Dr. Jens Huober et al. Novartis	Metastatic Breast Cancer	2003/3/1	Phase 4
NCT00379015	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan	Breast Cancer	2006/1/1	Phase 2
NCT04109391	Tanvex BioPharma USA, Inc.	HER2-positive Breast Cancer Early-stage Breast Cancer Breast Cancer Breast Neoplasms Stage II Breast Cancer Stage IIIA Breast Cancer	2019/8/23	Phase 3
NCT00915018	Puma Biotechnology, Inc.	Breast Cancer	2009/8/21	Phase 2
NCT04922008	Fudan University	Breast Cancer	2021/7/1	Phase 2
NCT00118053	University of Medicine and Dentistry of New Jersey National Cancer Institute (NCI) Aventis Pharmaceuticals Rutgers, The State University of New Jersey	Breast Cancer	April 2005	Phase 2
NCT00876395	Novartis Pharmaceuticals Novartis	Breast Cancer	2009/9/10	Phase 3
NCT00381901	National Cancer Institute, France National Cancer Institute (NCI)	Breast Cancer	2006/5/1	Phase 3
NCT00431704	National Cancer Institute, Naples	Metastatic Breast Cancer	2007/10/1	Phase 2
NCT00934856	Hoffmann-La Roche	Breast Cancer	2009/7/1	Phase 1 Phase 2
NCT00811993	Hoffmann-La Roche	Neoplasms	2009/2/1	Phase 1
NCT04430738	Seagen Inc.	Colorectal Carcinoma Gastric Adenocarcinoma GEJ Adenocarcinoma Esophageal Adenocarcinoma Cholangiocarcinoma Gallbladder Carcinoma	2020/9/15	Phase 1 Phase 2
NCT04957212	Cinnagen	HER2-positive Breast Cancer	2018/8/11	Phase 3
NCT02625441	Helsinki University Central Hospital	Breast Cancer	2015/12/1	Phase 3
NCT03910712	Peking Union Medical College Hospital	Breast Cancer Female HER2-positive Breast Cancer Hormone Receptor Positive Malignant Neoplasm of Breast Metastatic Breast Cancer Breast Diseases Hormone Receptor Positive Tumor	2019/6/1	Phase 2
NCT01897441	Albert Einstein College of Medicine National Cancer Institute (NCI)	Stage IIA Breast Cancer Stage IIB Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer	2013/6/1	Not Applicable

NCT01501487	Agendia University of South Florida University of Miami Morton Plant Mease Health Care AdventHealth Plano Cancer Center Ohio State University Comprehensive Cancer Center University of Oklahoma University of South Alabama	Breast Cancer	2011/10/1	Phase 4
NCT01705340	National Cancer Institute (NCI)	Adenocarcinoma of the Gastroesophageal Junction HER2-positive Breast Cancer Male Breast Cancer Recurrent Breast Cancer Recurrent Esophageal Cancer Recurrent Gastric Cancer Stage IIIC Breast Cancer Stage IIIC Esophageal Cancer Stage IIIC Gastric Cancer Stage IV Breast Cancer Stage IV Esophageal Cancer Stage IV Gastric Cancer	2012/9/1	Phase 1
NCT03417544	Nancy Lin, MD Genentech, Inc. Dana-Farber Cancer Institute	HER2-positive Metastatic Breast Cancer Central Nervous System Metastases	2018/2/21	Phase 2
NCT00005842	National Cancer Institute (NCI)	Cancer	2000/6/1	Phase 1
NCT00022529	National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	2001/7/1	Phase 1
NCT00042809	National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	2002/5/1	Phase 1
NCT01816035	University of Washington National Cancer Institute (NCI)	HER2+Neu Positive Recurrent Breast Carcinoma Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer	2014/6/1	Phase 1
NCT03013218	ALX Oncology Inc.	Metastatic Cancer Solid Tumor Advanced Cancer NonHodgkin Lymphoma	2017/2/3	Phase 1
NCT01565083	Hoffmann-La Roche	Breast Cancer	April 2012	Phase 2
NCT04661150	Hoffmann-La Roche	Gastric Cancer Gastroesophageal Junction Adenocarcinoma	2021/3/12	Phase 2
NCT02062983	National Guard Health Affairs	Breast Cancer	2012/6/1	
NCT01290718	Hoffmann-La Roche	Breast Cancer	2011/12/1	Phase 2
NCT03947242	Henan Cancer Hospital	HER2 Positive Breast Cancer	2019/6/1	Not Applicable
NCT00238420	National Cancer Institute (NCI) Radiation Therapy Oncology Group	Bladder Urothelial Carcinoma Stage I Bladder Cancer AJCC v6 and v7 Stage II Bladder Cancer AJCC v6 and v7 Stage III Bladder Cancer AJCC v6 and v7	2005/7/26	Phase 1 Phase 2
NCT00129896	Spanish Breast Cancer Research Group Cephalon Sanofi Hoffmann-La Roche Amgen	Breast Cancer	2004/1/1	Phase 1 Phase 2
NCT04553770	Jonsson Comprehensive Cancer Center Translational Research in Oncology-U.S Daiichi Sankyo Co., Ltd.	Early-stage Breast Cancer Hormone Receptor Positive Breast Carcinoma Invasive Breast Cancer Stage II Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer Stage III Breast Cancer	2020/10/9	Phase 2

NCT03180242	EirGenix, Inc.	Healthy	2016/3/22	Phase 1
NCT01503983	Fundación para el Progreso de la Oncología en Cantabria	Stage IV Gastric Cancer With Metastasis	2011/8/1	Phase 2
NCT00769470	Translational Oncology Research International National Cancer Institute (NCI) University of California, Los Angeles	Breast Cancer	April 2009	Phase 2
NCT00337649	Hoffmann-La Roche	Breast Cancer	2004/5/1	Phase 2
NCT00133796	Mothaffar Rimawi Genentech, Inc. Baylor Breast Care Center	BREAST CANCER	2001/10/1	Phase 2
NCT02238509	Consorzio Oncotech Clinical Research Technology S.r.l.	Metastatic Breast Cancer	2014/11/1	Phase 2
NCT00885755	Hoffmann-La Roche	Breast Cancer	2009/8/13	Phase 2
NCT00968682	Cancer Trials Ireland	Breast Cancer Cardiac Toxicity	April 2008	
NCT02139358	H. Lee Moffitt Cancer Center and Research Institute Genentech, Inc.	Breast Cancer	2014/9/5	Phase 1 Phase 2
NCT01771458	Institut Curie	Reccurent+Metastatic Solid Tumor Disease	2012/10/1	Phase 2
NCT01026142	Hoffmann-La Roche	Breast Cancer	2010/1/26	Phase 3
NCT02060253	Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) Synta Pharmaceuticals Corp. New York University Cancer Institute	HER2-positive Breast Cancer Male Breast Cancer Recurrent Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer	April 2014	Phase 1
NCT00016276	National Cancer Institute (NCI)	Cardiac Toxicity Inflammatory Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IV Breast Cancer	2001/5/1	Phase 3
NCT02448420	SOLTI Breast Cancer Research Group	Metastatic Breast Cancer	2015/7/1	Phase 2
NCT01386580	BBB-Therapeutics B.V.	Brain Metastases Lung Cancer Breast Cancer Melanoma Malignant Glioma	2011/7/1	Phase 1 Phase 2
NCT00256243	Rita Sanghvi, Mehta University of California, Irvine	Breast Cancer	April 2004	Phase 2
NCT00104949	Southwest Oncology Group National Cancer Institute (NCI)	Sarcoma	2005/7/1	Phase 2
NCT00079326	National Cancer Institute (NCI)	HER2-positive Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer	2004/1/1	Phase 2
NCT01479179	M.D. Anderson Cancer Center Amgen	Breast Cancer	2012/11/1	Phase 1 Phase 2
NCT04931342	Hoffmann-La Roche GOG Foundation European Network of Gynaecological Oncological Trial Groups (ENGOT)	Ovarian Cancer	2021/10/12	Phase 2
NCT00427427	Jonsson Comprehensive Cancer Center	Breast Cancer	2007/1/1	Phase 2
NCT01137994	GlaxoSmithKline	Neoplasms, Breast	2011/10/1	Phase 2
NCT01388647	Vector Oncology Eisai Inc.	HER-2 Positive Breast Cancer	2011/8/1	Phase 1 Phase 2

NCT01922921	University of Washington National Cancer Institute (NCI) Office of Cancer Complementary and Alternative Medicine	HER2+Neu Positive Recurrent Breast Carcinoma Stage IV Breast Cancer	2014/2/5	Phase 1 Phase 2
NCT01912963	Dana-Farber Cancer Institute Eisai Inc. Genentech, Inc.	HER2-positive Breast Cancer Metastatic Breast Cancer	2013/9/1	Phase 2
NCT00464646	NSABP Foundation Inc Genentech, Inc. International Drug Development Institute	Breast Cancer	2007/5/1	Phase 2
NCT00436566	Mayo Clinic National Cancer Institute (NCI)	Breast Cancer Cardiac Toxicity	2007/3/16	Phase 2
NCT04193059	Fudan University	Breast Cancer	2018/8/1	Phase 3
NCT00950300	Hoffmann-La Roche	Breast Cancer	2009/10/16	Phase 3
NCT00433407	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI)	Breast Cancer Lung Cancer Ovarian Cancer Prostate Cancer Sarcoma Unspecified Adult Solid Tumor, Protocol Specific	2005/8/1	Not Applicable
NCT04683445	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Breast Cancer	2020/12/1	
NCT02393248	Incyte Corporation	Lung Cancer Solid Tumor Gastric Cancer Urothelial Cancer Endometrial Cancer Multiple Myeloma Myeloproliferative Neoplasms Breast Cancer Cholangiocarcinoma UC MPN	2015/2/27	Phase 1 Phase 2
NCT02562378	MedSIR Roche Pharma AG Experior	Breast Cancer	2015/10/1	Phase 1
NCT04551521	German Cancer Research Center	Metastatic or Locally Advanced Malignancies	2021/8/1	Phase 2
NCT02721641	Hoffmann-La Roche	Neoplasms	1999/6/1	Phase 3
NCT00826267	Boehringer Ingelheim	Breast Neoplasms	2009/1/1	Phase 2
NCT04704934	Daiichi Sankyo, Inc. AstraZeneca	Gastric Cancer, Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	2021/5/21	Phase 3
NCT00387907	Sanofi	Advanced Breast Cancer Breast Cancer Metastatic Breast Cancer	2006/10/1	Phase 2
NCT04740918	Hoffmann-La Roche	Metastatic Breast Cancer	2021/6/7	Phase 3
NCT02250209	Chinese PLA General Hospital	Gastric Cancer	2014/7/1	Phase 2
NCT03273595	Xijing Hospital	Neoplasms, Breast	2016/7/1	Phase 2
NCT01344863	Hoffmann-La Roche	Healthy Volunteer	April 2011	Phase 1
NCT00625898	NSABP Foundation Inc Cancer International Research Group (CIRG) Hoffmann-La Roche Genentech, Inc.	Breast Cancer	April 2008	Phase 3
NCT04066790	Shanghai Jiao Tong University School of Medicine Jiangsu HengRui Medicine Co., Ltd.	Breast Cancer	2019/9/9	Phase 2
NCT00758134	Armando Santoro, MD Istituto Clinico Humanitas	NON-SMALL CELL LUNG CANCER	2008/7/1	Phase 2
NCT03988036	West German Study Group Merck Sharp & Dohme Corp. NanoString Technologies, Inc.	Breast Cancer	2020/8/18	Phase 2

NCT00398567	Puma Biotechnology, Inc.	Advanced Breast Cancer	April 4, 2007	Phase 1 Phase 2
NCT01387295	Dorte Nielsen Herlev Hospital	Metastatic Breast Cancer Liver Metastases	April 2010	Phase 2
NCT00807859	Amgen	Breast Cancer Breast Neoplasms Breast Tumors Cancer Locally Recurrent and Metastatic Breast Cancer Metastases Metastatic Cancer Oncology Solid Tumors Tumors	2009/3/9	Phase 1
NCT00216073	Hoosier Cancer Research Network Sanofi Hoffmann-La Roche Walther Cancer Institute	Metastatic Breast Cancer	2004/3/1	Phase 2
NCT02598427	Kimberly Blackwell Duke University	HER2 Positive Untreated Metastatic Breast Cancer Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer	2017/5/1	Phase 1
NCT02748213	Hoffmann-La Roche	Breast Cancer	2002/2/1	Phase 2
NCT01649271	Boehringer Ingelheim	Breast Neoplasms Stomach Neoplasms	2012/7/23	Phase 1
NCT03747120	Cedars-Sinai Medical Center Merck Sharp & Dohme Corp.	HER2-positive Breast Cancer Breast Cancer	2019/1/25	Phase 2
NCT04150640	University of Wisconsin, Madison Ipsen	Esophageal Adenocarcinoma Gastric Adenocarcinoma	2020/7/13	Phase 2
NCT00769379	National Cancer Institute (NCI) NRG Oncology	Breast Ductal Carcinoma In Situ	2008/11/10	Phase 3
NCT04670796	Shanghai Henlius Biotech	Healthy	2021/3/2	Phase 1
NCT03242239	Alteogen, Inc. Cristália Produtos Químicos Farmacêuticos Ltda.	Healthy	2016/2/9	Phase 1
NCT04457596	Alliance for Clinical Trials in Oncology National Cancer Institute (NCI) Seagen Inc.	Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 HER2 Positive Breast Carcinoma Invasive Breast Carcinoma Multifocal Breast Carcinoma Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8 Synchronous Bilateral Breast Carcinoma	2021/1/6	Phase 3
NCT00193076	SCRI Development Innovations, LLC Eli Lilly and Company Genentech, Inc.	Breast Cancer	2003/11/1	Phase 2

NCT02376413	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Local Recurrence of Malignant Tumor of Breast	2015/3/1	
NCT00019812	National Institutes of Health Clinical Center (CC) National Cancer Institute (NCI)	Breast Cancer	1999/8/1	Phase 2
NCT00670982	Harold J. Burstein, MD, PhD Brigham and Women's Hospital Beth Israel Deaconess Medical Center Massachusetts General Hospital Genentech, Inc. New Hampshire Oncology-Hematology PA Lowell General Hospital Hartford Hospital Dana-Farber Cancer Institute	Breast Cancer	2008/5/1	Phase 2
NCT04197687	Academic and Community Cancer Research United National Cancer Institute (NCI)	Breast Adenocarcinoma Stage II Breast Cancer AJCC v6 and v7 Stage IIA Breast Cancer AJCC v6 and v7 Stage IIB Breast Cancer AJCC v6 and v7 Stage III Breast Cancer AJCC v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7	2020/2/20	Phase 2
NCT03457896	NSABP Foundation Inc Puma Biotechnology, Inc.	Metastatic Colorectal Cancer	2018/5/18	Phase 2
NCT00430001	Danish Breast Cancer Cooperative Group Hoffmann-La Roche Sanofi	Breast Cancer	2005/5/1	Phase 3
NCT00004067	NSABP Foundation Inc National Cancer Institute (NCI)	Breast Cancer	2000/2/1	Phase 3
NCT00004888	National Cancer Institute (NCI)	Recurrent Breast Cancer Stage IV Breast Cancer	2001/1/1	Phase 2
NCT04285671	Jonsson Comprehensive Cancer Center Eli Lilly and Company Genentech, Inc.	Metastatic Lung Non-Small Cell Carcinoma Refractory Lung Non-Small Cell Carcinoma Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8	2021/1/29	Phase 1 Phase 2
NCT02344472	Prof. W. Janni Roche Pharma AG Novartis Pharmaceuticals Eisai GmbH Celgene Corporation University of Ulm	Metastatic Breast Cancer	2015/9/1	Phase 3
NCT03680560	Cogent Biosciences, Inc.	Solid Tumor HER-2 Protein Overexpression	2019/3/13	Phase 1
NCT04578106	Fundacio Clinic Barcelona SOLT1 Breast Cancer Research Group Roche Pharma AG	HER2-positive Breast Cancer Stage I Breast Cancer	2020/9/23	Phase 2
NCT03390608	Karolinska Institutet The Swedish Society of Medicine The Swedish Breast Cancer Association (BRO) Swedish Breast Cancer Group	Breast Cancer	1977/1/1	
NCT01384253	Orano Med LLC	Breast Neoplasms Peritoneal Neoplasms Ovarian Neoplasms Pancreatic Neoplasms Stomach Neoplasms	2011/7/1	Phase 1
NCT01242449	Vejele Hospital	Breast Cancer	2010/11/1	Phase 2

NCT00448279	Hoffmann-La Roche	Breast Cancer	April 2007	Phase 3
NCT04168931	AC Camargo Cancer Center	Gastric Cancer Stage IV	2020/1/1	Phase 2
NCT04973319	Shengjing Hospital	Breast Cancer	2021/8/1	Phase 3
NCT00567190	Genentech, Inc. Hoffmann-La Roche	Metastatic Breast Cancer	2008/2/12	Phase 3
NCT03199885	National Cancer Institute (NCI) NRG Oncology	Breast Adenocarcinoma Metastatic Breast Adenocarcinoma Recurrent Breast Carcinoma Stage III Breast Cancer AJCC v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7 Unresectable Breast Carcinoma	2019/3/12	Phase 3
NCT00006228	National Cancer Institute (NCI)	HER2-positive Breast Cancer Male Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer	2000/7/1	Phase 2
NCT00960960	Genentech, Inc.	Breast Cancer	2009/8/1	Phase 1
NCT03735966	Henan Cancer Hospital	HER2 Positive Breast Cancer	2018/11/20	Phase 2
NCT04082364	MacroGenics Zai Lab (Shanghai) Co., Ltd.	Gastric Cancer Gastroesophageal Junction Cancer HER2-positive Gastric Cancer	2019/9/30	Phase 2 Phase 3
NCT00912340	Emory University Genentech, Inc. Novartis Pharmaceuticals	Breast Cancer	2009/5/1	Phase 2
NCT00755313	University of California, San Francisco National Cancer Institute (NCI)	Breast Cancer Chemotherapeutic Agent Toxicity Cognitive+Functional Effects Fatigue Long-term Effects Secondary to Cancer Therapy in Adults Neurotoxicity Psychosocial Effects of Cancer and Its Treatment	2007/5/1	
NCT02896855	Hoffmann-La Roche	Breast Cancer	2016/9/13	Phase 3
NCT00003740	Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI)	Prostate Cancer	1998/10/1	Phase 2
NCT00397501	OHSU Knight Cancer Institute National Cancer Institute (NCI)	Brain and Central Nervous System Tumors Breast Cancer Cognitive+Functional Effects Drug+Agent Toxicity by Tissue+Organ Psychosocial Effects of Cancer and Its Treatment	2013/10/1	Phase 1 Phase 2
NCT00028535	National Cancer Institute (NCI)	Male Breast Cancer Recurrent Breast Cancer Recurrent Endometrial Carcinoma Recurrent Gastric Cancer Recurrent Non-small Cell Lung Cancer Recurrent Ovarian Epithelial Cancer Recurrent Small Cell Lung Cancer	2001/11/1	Phase 1
NCT01132664	Novartis Pharmaceuticals Novartis	Metastatic Breast Cancer HER2+ Breast Cancer	2010/5/1	Phase 1 Phase 2
NCT01953926	Puma Biotechnology, Inc.	Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations	2013/9/30	Phase 2

NCT01937117	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Translational Breast Cancer Research Consortium Genentech, Inc.	Breast Cancer	2014/1/30	Phase 2
NCT02015676	Hoffmann-La Roche	Breast Cancer	2001/7/1	Phase 1 Phase 2
NCT00976989	Hoffmann-La Roche	Breast Cancer	2009/11/1	Phase 2
NCT03433313	EirGenix, Inc.	Breast Cancer	2018/10/16	Phase 3
NCT00963547	Merck Sharp & Dohme Corp.	Advanced Solid Tumors Breast Cancer	2009/9/15	Phase 1
NCT02624973	Haukeland University Hospital Helse Vest Pfizer AstraZeneca	Breast Cancer	April 15, 2016	Phase 2
NCT05048797	AstraZeneca Daiichi Sankyo, Inc.	Locally Advanced or Metastatic Non-Small Cell Lung Cancer	2021/10/29	Phase 3
NCT01325207	Northwestern University	Breast Cancer	2011/8/1	Phase 1 Phase 2
NCT00266110	UNC Lineberger Comprehensive Cancer Center National Cancer Institute (NCI) Susan G. Komen Breast Cancer Foundation	Breast Cancer	2005/12/1	Phase 2
NCT03846583	Dana-Farber Cancer Institute Eli Lilly and Company	Breast Cancer	2020/6/28	Phase 1
NCT00242203	Washington University School of Medicine Novartis Pfizer	Breast Neoplasms	2002/10/1	Phase 2
NCT01674062	Hoffmann-La Roche	Breast Cancer	2006/5/1	Phase 2
NCT03412643	NSABP Foundation Inc Celcuity, LLC Genentech, Inc.	HER2-negative Breast Cancer	2018/5/14	Phase 2
NCT00004856	National Cancer Institute (NCI)	Distal Urethral Cancer Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter Proximal Urethral Cancer Recurrent Bladder Cancer Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter Recurrent Urethral Cancer Stage IV Bladder Cancer Transitional Cell Carcinoma of the Bladder Urethral Cancer Associated With Invasive Bladder Cancer	2002/7/1	Phase 2
NCT03153163	Hoffmann-La Roche	Breast Neoplasms	2017/6/20	Phase 1
NCT01228045	National University Hospital, Singapore National Cancer Centre, Singapore	Gastric Cancer	2011/2/1	Phase 2
NCT00140140	Celgene	Stage IV (Metastatic) Breast Cancer	2005/8/1	Phase 1 Phase 2
NCT04188548	Eli Lilly and Company	Breast Cancer Advanced Breast Cancer Metastatic Breast Cancer Endometrial Cancer	2019/12/10	Phase 1
NCT00875238	Vanderbilt University National Cancer Institute (NCI) Vanderbilt University Medical Center	Breast Cancer Cardiac Toxicity Cardiovascular Complications	2008/6/1	
NCT02605915	Hoffmann-La Roche	HER2-Positive Metastatic Breast Cancer HER2-Negative Metastatic Breast Cancer Locally Advanced or Early Breast Cancer	2015/12/31	Phase 1

NCT00820222	Novartis Pharmaceuticals Novartis	Metastases, Brain	April 14, 2009	Phase 3
NCT00788333	Bristol-Myers Squibb	Breast Cancer	2009/7/1	Phase 1 Phase 2
NCT00964704	Hoffmann-La Roche	Breast Cancer	2011/3/1	Phase 2
NCT04905667	Genor Biopharma Co., Ltd.	Breast Cancer	2019/11/13	Phase 1
NCT00093808	Alliance for Clinical Trials in Oncology National Cancer Institute (NCI)	Breast Cancer	2004/8/1	Phase 2
NCT01196052	Hoffmann-La Roche	Breast Cancer	2010/10/1	Phase 2
NCT01688609	National Cancer Institute (NCI)	HER2-positive Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer	2012/7/1	Phase 2
NCT04266249	ECOG-ACRIN Cancer Research Group National Cancer Institute (NCI) Eastern Cooperative Oncology Group	Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Invasive Breast Carcinoma Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8	2020/2/11	Phase 2
NCT02771795	Samsung Bioepis Co., Ltd.	Breast Neoplasms	April 2016	
NCT00999804	Baylor Breast Care Center Translational Breast Cancer Research Consortium GlaxoSmithKline	Breast Cancer	2011/10/1	Phase 2
NCT04858516	Guangdong Provincial People's Hospital	Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer	April 30, 2021	Phase 2
NCT01271920	Novartis Pharmaceuticals Novartis	Advanced HER2-positive Breast Cancer	2010/9/1	Phase 1 Phase 2
NCT04989816	AstraZeneca Daiichi Sankyo Co., Ltd.	Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	2021/8/20	Phase 2
NCT04220203	Seagen Inc. Parexel	HER2-positive Breast Cancer		
NCT03734029	Daiichi Sankyo, Inc. Daiichi Sankyo Co., Ltd. AstraZeneca	Breast Cancer	2018/12/27	Phase 3
NCT01764022	Biocad	Human Epithelial Receptor (HER)-2 Positive Breast Cancer	2012/10/1	Phase 3
NCT02297230	NYU Langone Health	Breast Cancer	2002/6/1	Phase 1 Phase 2
NCT00085020	Jonsson Comprehensive Cancer Center GlaxoSmithKline	Breast Cancer	2004/3/1	Phase 1